How to use interleukin-2
IL-2 variants and fusion proteins address the limitations of existing IL-2 therapies by enhancing Treg levels and modulating immunosuppression, offering safer and more effective treatment options for diseases and transplant rejection.
Patent Information
- Application Number
- JP2024532776
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-02
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-19
AI Technical Summary
There is an unmet need for novel IL-2-based agents that are safe and effective for treating various diseases and conditions, as existing IL-2 therapies are limited by severe toxicity and are only effective for a small subset of eligible patients.
The development of IL-2 variants and fusion proteins, such as those with an Fc region and specific amino acid substitutions, to enhance safety and efficacy by selectively increasing regulatory T cells (Tregs) and modulating immunosuppression, including methods for administering these agents before, during, or after transplantation.
The IL-2 variants and fusion proteins significantly increase Treg levels, providing effective immunosuppression and improving transplant rejection prevention and allograft survival, with reduced toxicity and improved therapeutic outcomes.
Smart Images

Figure 2024543209000286 
Figure 2024543209000287 
Figure 2024543209000288
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Patent Application No. 63 / 284,978, filed December 1, 2021, and U.S. Provisional Patent Application No. 63 / 348,201, filed June 2, 2022. The contents of the foregoing applications are incorporated herein by reference in their entireties. [Background technology]
[0002] Interleukin-2 (IL-2) is a cytokine that regulates the activity of the immune system. It is produced by white blood cells such as T cells, natural killer (NK) cells, dendritic cells, and macrophages in response to antigenic or mitogenic stimuli. IL-2 is important for T cell proliferation, B cell stimulation, and other activities related to immunity and tolerance. It is part of the body's adaptive immune response and distinguishes foreign from host antigens. IL-2 mediates its effects by binding to the IL-2 receptor, which then activates downstream signaling events.
[0003] Human IL-2 is an FDA approved drug for the treatment of diseases such as metastatic renal carcinoma and melanoma. The use of IL-2 in eligible patients can be limited due to the severe toxicities associated with IL-2 therapy, with only a small subset of eligible patients actually undergoing therapy. Toxicities associated with IL-2 therapy can include severe fever, nausea, vomiting, vascular leakage, and severe hypotension. However, despite these toxicities, IL-2 is typically effective for its approved indications.
[0004] There remains an unmet need for novel IL-2-based agents that are well characterized for the development of safe and effective therapeutics for patients with a variety of diseases and conditions amenable to treatment with IL-2. Summary of the Invention [Means for solving the problem]
[0005] In one aspect, the disclosure provides a method of treating transplant rejection or a symptom thereof, comprising administering to a subject in need thereof an effective amount of an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, thereby treating the transplant rejection or a symptom thereof.
[0006] In one embodiment, the transplant is a heart transplant.
[0007] In one embodiment, the level of Tregs in the subject is increased by about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to the level of Tregs in the subject prior to administration of the IL-2 fusion protein. In one embodiment, the level of Tregs is determined in a sample from the subject.
[0008] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant described herein.
[0009] In one embodiment, the IL-2 variant comprises (i) (a) the amino acid substitution H16L or H16N, (b) the amino acid substitution I92S, or (c) both (a) and (b), and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.
[0010] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 comprising an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises any of the amino acid sequences of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker is a (G 4 S) 4 (SEQ ID NO: 48). In one embodiment, the fusion protein forms a dimer.
[0011] In one embodiment, the fusion protein comprises an amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008, or 1009, an amino acid sequence that is at least 95% identical thereto or differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, or a functional fragment thereof.
[0012] In one embodiment, the method further comprises administering to the subject an immunosuppressant agent, hi one embodiment, the immunosuppressant agent comprises rapamycin.
[0013] In one embodiment, the subject is a human or non-human primate, hi one embodiment, the subject is a mouse.
[0014] In another aspect, the present disclosure provides a method of preventing transplant rejection or a symptom thereof, comprising administering to a subject in need thereof an effective amount of an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, thereby preventing transplant rejection or a symptom thereof.
[0015] In one embodiment, the transplant is a heart transplant.
[0016] In one embodiment, the level of Tregs in the subject is increased by about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to the level of Tregs in the subject prior to administration of the IL-2 fusion protein. In one embodiment, the level of Tregs is determined in a sample from the subject.
[0017] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant described herein.
[0018] In one embodiment, the IL-2 variant comprises (i) (a) the amino acid substitution H16L or H16N, (b) the amino acid substitution I92S, or (c) both (a) and (b), and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.
[0019] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 comprising an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises any of the amino acid sequences of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker is a (G 4 S) 4 (SEQ ID NO: 48). In one embodiment, the fusion protein forms a dimer.
[0020] In one embodiment, the fusion protein comprises an amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008, or 1009, an amino acid sequence that is at least 95% identical thereto or differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, or a functional fragment thereof.
[0021] In one embodiment, the method further comprises administering to the subject an immunosuppressant agent, hi one embodiment, the immunosuppressant agent comprises rapamycin.
[0022] In one embodiment, the subject is a human or non-human primate, hi one embodiment, the subject is a mouse.
[0023] In yet another aspect, the disclosure provides a method of modulating (e.g., increasing or inducing) immunosuppression for transplantation, comprising administering to a subject in need thereof an effective amount of an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, thereby modulating (e.g., increasing or inducing) immunosuppression for transplantation.
[0024] In one embodiment, the subject has undergone, is undergoing, or will undergo a transplant at the time the IL-2 agent is administered to the subject, hi one embodiment, the transplant is a heart transplant.
[0025] In one embodiment, the level of Tregs in the subject is increased by about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to the level of Tregs in the subject prior to administration of the IL-2 fusion protein. In one embodiment, the level of Tregs is determined in a sample from the subject.
[0026] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant described herein.
[0027] In one embodiment, the IL-2 variant comprises (i) (a) the amino acid substitution H16L or H16N, (b) the amino acid substitution I92S, or (c) both (a) and (b), and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.
[0028] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 comprising an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises any of the amino acid sequences of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker is a (G 4 S) 4 (SEQ ID NO: 48). In one embodiment, the fusion protein forms a dimer.
[0029] In one embodiment, the fusion protein comprises an amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008, or 1009, an amino acid sequence that is at least 95% identical thereto or differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, or a functional fragment thereof.
[0030] In one embodiment, the method further comprises administering to the subject an immunosuppressant agent, hi one embodiment, the immunosuppressant agent comprises rapamycin.
[0031] In one embodiment, the subject is a human or non-human primate, hi one embodiment, the subject is a mouse.
[0032] In yet another aspect, the disclosure provides a method of conditioning a subject prior to transplantation, comprising administering to a subject in need thereof an effective amount of an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, thereby conditioning the subject prior to transplantation.
[0033] In one embodiment, the transplant is a heart transplant.
[0034] In one embodiment, the level of Tregs in the subject is increased by about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to the level of Tregs in the subject prior to administration of the IL-2 fusion protein. In one embodiment, the level of Tregs is determined in a sample from the subject.
[0035] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant described herein.
[0036] In one embodiment, the IL-2 variant comprises (i) (a) the amino acid substitution H16L or H16N, (b) the amino acid substitution I92S, or (c) both (a) and (b), and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.
[0037] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 comprising an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises any of the amino acid sequences of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker is a (G 4 S) 4 (SEQ ID NO: 48). In one embodiment, the fusion protein forms a dimer.
[0038] In one embodiment, the fusion protein comprises an amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008, or 1009, an amino acid sequence that is at least 95% identical thereto or differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, or a functional fragment thereof.
[0039] In one embodiment, the method further comprises administering to the subject an immunosuppressant agent, hi one embodiment, the immunosuppressant agent comprises rapamycin.
[0040] In one embodiment, the subject is a human or non-human primate, hi one embodiment, the subject is a mouse.
[0041] In another aspect, the disclosure provides a method of selectively increasing Tregs, comprising administering to a subject in need thereof an effective amount of an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, wherein the subject has received, is receiving, or will receive a transplant, thereby selectively increasing Tregs.
[0042] In one embodiment, the transplant is a heart transplant.
[0043] In one embodiment, the level of Tregs in the subject is increased by about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to the level of Tregs in the subject prior to administration of the IL-2 fusion protein. In one embodiment, the level of Tregs is determined in a sample from the subject.
[0044] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant described herein.
[0045] In one embodiment, the IL-2 variant comprises (i) (a) the amino acid substitution H16L or H16N, (b) the amino acid substitution I92S, or (c) both (a) and (b), and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.
[0046] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 comprising an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises any of the amino acid sequences of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker is a (G 4 S) 4 (SEQ ID NO: 48). In one embodiment, the fusion protein forms a dimer.
[0047] In one embodiment, the fusion protein comprises an amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008, or 1009, an amino acid sequence that is at least 95% identical thereto or differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, or a functional fragment thereof.
[0048] In one embodiment, the method further comprises administering to the subject an immunosuppressant agent, hi one embodiment, the immunosuppressant agent comprises rapamycin.
[0049] In one embodiment, the subject is a human or non-human primate, hi one embodiment, the subject is a mouse.
[0050] In yet another aspect, the disclosure provides a method of treating a cardiac disease or symptom thereof, comprising administering to a subject in need thereof an effective amount of an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, and providing a heart transplant to the subject, thereby treating the cardiac disease or symptom thereof.
[0051] In one embodiment, a heart transplant is provided to the subject prior to, concurrently with, or following administration of the IL-2 fusion protein.
[0052] In one embodiment, the level of Tregs in the subject is increased by about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to the level of Tregs in the subject prior to administration of the IL-2 fusion protein. In one embodiment, the level of Tregs is determined in a sample from the subject.
[0053] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant described herein.
[0054] In one embodiment, the IL-2 variant comprises (i) (a) the amino acid substitution H16L or H16N, (b) the amino acid substitution I92S, or (c) both (a) and (b), and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.
[0055] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 comprising an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises any of the amino acid sequences of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker is a (G 4 S) 4 (SEQ ID NO: 48). In one embodiment, the fusion protein forms a dimer.
[0056] In one embodiment, the fusion protein comprises an amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008, or 1009, an amino acid sequence that is at least 95% identical thereto or differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, or a functional fragment thereof.
[0057] In one embodiment, the method further comprises administering to the subject an immunosuppressant agent, hi one embodiment, the immunosuppressant agent comprises rapamycin.
[0058] In one embodiment, the subject is a human or non-human primate, hi one embodiment, the subject is a mouse.
[0059] In another aspect, the present disclosure provides a combination comprising an IL-2 agent as described herein, such as an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, and a transplant. In one embodiment, the transplant is a heart transplant. In one embodiment, the transplant further comprises one or more additional immunosuppressants, such as rapamycin.
[0060] In one embodiment, the combination is for use in treating or preventing transplant rejection in a subject. In one embodiment, the transplant rejection is heart transplant rejection. In one embodiment, the IL-2 agent is administered to the subject before, during, and / or after transplantation.
[0061] In one embodiment, the combination is for use in modulating (e.g., increasing or inducing) immune suppression in a subject. In one embodiment, the combination is for use in selectively increasing T regulatory cells in a subject. In one embodiment, the subject is a human or non-human primate. In one embodiment, the subject is a mouse.
[0062] In one aspect, the disclosure provides an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of treating transplant rejection or a symptom thereof in a subject, as described herein.
[0063] In another aspect, the disclosure provides an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of preventing transplant rejection or a symptom thereof in a subject, as described herein.
[0064] In yet another aspect, the disclosure provides an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of modulating (e.g., increasing or inducing) immunosuppression for transplantation in a subject, as described herein.
[0065] In yet another aspect, the disclosure provides an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of conditioning a subject prior to transplantation, as described herein.
[0066] In another aspect, the disclosure provides an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of selectively increasing Tregs in a subject, where the subject has undergone, has undergone, or is going to undergo a transplant, as described herein.
[0067] In yet another aspect, the disclosure provides an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, in combination with heart transplantation for use in a method of treating a cardiac disease or symptom thereof in a subject, as described herein.
[0068] In one aspect, the disclosure provides for the use of an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, in the manufacture of a medicament for treating transplant rejection or a symptom thereof in a subject, as described herein.
[0069] In another aspect, the disclosure provides for the use of an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, in the manufacture of a medicament for preventing transplant rejection or a symptom thereof in a subject, as described herein.
[0070] In yet another aspect, the disclosure provides for the use of an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, in the manufacture of a medicament for modulating (e.g., increasing or inducing) immunosuppression for transplantation in a subject, as described herein.
[0071] In yet another aspect, the disclosure provides for the use of an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, in the manufacture of a medicament for conditioning a subject prior to transplantation, as described herein.
[0072] In another aspect, the disclosure provides for the use of an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, in the manufacture of a medicament for selectively increasing Tregs in a subject, where the subject has undergone, has undergone, or is going to undergo a transplant.
[0073] In yet another aspect, the disclosure provides for the use of an IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, in combination with heart transplantation in the manufacture of a medicament for treating a cardiac disease or a symptom thereof in a subject, as described herein. [Brief description of the drawings]
[0074] [Figure 1A]Figures 1A and 1B are a series of flow cytometry plots showing that exemplary IL-2 muteins promoted in vitro mouse inducible Treg (iTreg) development in the presence of TGF-β. Treatment in the absence (Figure 1A) or presence (Figure 1B) of 3ng / ml TGFβ1 is shown. Treatment with beads only, IL-2 / 0.5ug / ml, IL-2 / 5ug / ml, IL-2m 0.5ug / ml, or IL-2m 5ug / ml is also shown. X-axis: FL9-A: CD4 PB450-A, y-axis: FL1-A: YFP FITC-A. [Figure 1B] Figures 1A and 1B are a series of flow cytometry plots showing that exemplary IL-2 muteins promoted in vitro mouse inducible Treg (iTreg) development in the presence of TGF-β. Treatment in the absence (Figure 1A) or presence (Figure 1B) of 3ng / ml TGFβ1 is shown. Treatment with beads only, IL-2 / 0.5ug / ml, IL-2 / 5ug / ml, IL-2m 0.5ug / ml, or IL-2m 5ug / ml is also shown. X-axis: FL9-A: CD4 PB450-A, y-axis: FL1-A: YFP FITC-A. [Figure 2A] Figures 2A and 2B are immunoblots showing that exemplary IL-2 muteins promoted Stat5 tyrosine phosphorylation (Y694) signaling from IL-2R in Tregs. Figure 2A shows Tyr-694 with p-Stat5b indicated by arrow, Figure 2B shows total. Columns 1-4: beads only, columns 5-8: beads + IL-2 10ug / ml, columns 9-12: beads + IL-2m 10ug / ml. Fresh, 10min, 30min, and 60min. [Figure 2B]Figures 2A and 2B are immunoblots showing that exemplary IL-2 muteins promoted Stat5 tyrosine phosphorylation (Y694) signaling from IL-2R in Tregs. Figure 2A shows Tyr-694 with p-Stat5b indicated by arrow, Figure 2B shows total. Columns 1-4: beads only, columns 5-8: beads + IL-2 10ug / ml, columns 9-12: beads + IL-2m 10ug / ml. Fresh, 10min, 30min, and 60min. [Diagram 3] Figure 3 is a series of flow cytometry plots showing the expansion of circulating Tregs in vivo by injecting an exemplary IL-2 mutein. 10ug of IL-2 mutein was administered subcutaneously twice a week. Analysis of blood before treatment is shown. X-axis shows CD4 expression and y-axis shows Foxp3 expression. [Figure 4] Figure 4 is a graph showing survival of a mouse allograft model (BALB / c->C57BL / 6). Mice received RPM alone or two injections of IL-2 mutein prior to treatment and 0.5 mg / kg / day RPM for 14 days (Alzet). Prior to transplantation, an exemplary IL-2 mutein (IL-2C) extended survival of mouse cardiac allografts for >100 days. IL-2A mutein -50% Treg, IL-2C mutein -30% Treg, IL-2D mutein -20% Treg, nearly normal by day 10 after treatment. [Diagram 5] Figure 5 is a graph showing survival of a mouse cardiac allograft model (BALB / c -> C57BL / 6, n=5) receiving post-treatment IL-2C mutein (10ug / mouse / 2x / w / 3 weeks), demonstrating the efficacy of post-treatment IL-2C mutein therapy alone in mouse cardiac allograft recipients. [Figure 6A]Figure 6A is a graph showing survival of mouse cardiac allograft models (BALB / IL-2C->C57BL / 6, 4-5 / group) that received RPM alone or IL-2C mutein (10ug ip x 2 / week IL-2C from treatment) with RPM (0.5mg / kg / d RPM 14d (Alzet)) after transplantation. IL-2C mutein administration was stopped on day 21 after treatment or continued until day 80. C3H cardiac allografts were received on day 100. The results show that limited post-transplant IL-2C mutein extended mouse cardiac allograft survival until the end of the study period. [Figure 6B] Figure 6B is a series of flow cytometry plots illustrating CD4 expression (x-axis) and Foxp3 expression (y-axis) for the mouse cardiac allograft model and treatment shown in Figure 6 A. The rightmost flow cytometry plot corresponds to the rejecting recipient. [Figure 7] Figure 7 shows histological images showing donor-specific tolerance induced by IL-2C mutein therapy. Cardiac tissue from a recipient after continuous acceptance of a BALB / c cardiac allograft for >110 days (left), and acute rejection of a C3H cardiac allograft within 8-9 days (right) are shown. Three weeks of IL-2C and 14 days of low-dose RPM were administered (N=5 / group, H&E, x200). Donor-specific tolerance was induced by IL-2C mutein therapy. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0075] Detailed Description of the Invention The present disclosure is based, at least in part, on the discovery that a short course of therapy with selected IL-2 muteins can expand recipient Foxp3+ Treg cells and induce donor-specific allograft survival. Without wishing to be bound by theory, in some embodiments, IL-2 muteins promote iTreg development in vitro and in vivo, and their efficacy is believed to be superior to that of native IL-2 in promoting mouse allograft survival. As disclosed herein, pre- and post-treatment therapies prolonged allograft survival, especially when combined with a brief subtherapeutic course of RPM. For example, 3 weeks of post-treatment IL-2 mutein therapy + 2 weeks of rapamycin (RPM) induced long-term cardiac allograft survival. Hearts at >100 days showed essentially normal histology, and recipients rapidly rejected third-party cardiac allografts.
[0076] definition As used herein, the articles "a" and "an" refer to one or to more than one (eg, to at least one) of the grammatical object of the article.
[0077] The term "or" is used herein to mean, and is used interchangeably with, the term "and / or," unless context clearly indicates otherwise.
[0078] "About" and "approximately" are generally intended to mean an acceptable degree of error for a quantity measured given the nature or precision of the measurement. An exemplary degree of error is within 20 percent (%), typically within 10%, and more typically within 5% of a given value or range of values. When "about" or "approximately" is present before a series of numbers or ranges, it is understood that the "about" or "approximately" can modify each of the numbers in the series or range. Similarly, when "at least," "more than," "no more than," "less than," "no less than," or "within" is present before a series of numbers or ranges, it is understood that the "at least," "more than," "no more than," "less than," "no less than," or "within" can modify each of the numbers in the series or range. As used herein, a range includes both upper and lower limits.
[0079] The compositions and methods disclosed herein encompass polypeptides and nucleic acids having the identified sequences, or sequences substantially identical or similar thereto, e.g., sequences at least 85%, 90%, 95% identical or more to the identified sequences.
[0080] In the context of amino acid sequences, the term "substantially identical" is used herein to refer to a first amino acid sequence that contains a sufficient or minimal number of amino acid residues that are i) identical or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences may have a common structural domain and / or a common functional activity, such as an amino acid sequence that contains a common structural domain that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a reference sequence, e.g., a sequence provided herein.
[0081] In the context of nucleotide sequences, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or a minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having a common functional activity or encode a common structural polypeptide domain or a common functional polypeptide activity. A reference sequence is a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a reference sequence, e.g., a sequence provided herein.
[0082] The term "functional variant" refers to a polypeptide that has substantially the same amino acid sequence as a naturally occurring sequence, or is encoded by substantially the same nucleotide sequence, and is capable of one or more activities of the naturally occurring sequence.
[0083] Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.
[0084] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced into one or both of the first and second amino acid or nucleic acid sequences for optimal alignment, and non-homologous sequences can be ignored for comparison purposes). In a typical embodiment, the length of the reference sequence aligned for comparison purposes is at least 30%, e.g., at least 40%, 50%, 60%, e.g., at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at the corresponding amino acid positions or nucleotide positions are then compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position.
[0085] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences.
[0086] Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In one embodiment, percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm, which is implemented in the GAP program of the GCG software package (www.gcg.com) using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4, and a length weight of 1, 2, 3, 4, 5, or 6. In a particular embodiment, percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (www.gcg.com) using a NWSgapdna.CMP matrix, and a gap weight of 40, 50, 60, 70, or 80, and a length weight of 1, 2, 3, 4, 5, or 6. One preferred set of parameters (and those to be used unless otherwise specified) is a Blossum 62 scoring matrix, with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.
[0087] The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
[0088] The nucleic acid and protein sequences described herein can be used as a "query sequence" to perform searches against public databases to identify, for example, other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acids described herein. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the protein molecules described herein. To obtain gapped alignments for comparison purposes, gapped BLAST can be used as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See www.ncbi.nlm.nih.gov.
[0089] As used herein, the term "hybridize under low stringency, medium stringency, high stringency, or very high stringency conditions" describes hybridization and washing conditions. Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6, which is incorporated by reference. Aqueous and non-aqueous methods are described in that reference, either of which can be used. The specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride / sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC with 0.1% SDS at at least 50°C (for low stringency conditions, the temperature of the washes can be increased to 55°C); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by two washes in 0.2X SSC with 0.1% SDS at at least 50°C (for low stringency conditions, the temperature of the washes can be increased to 55°C); 3) high stringency hybridization conditions in 6×SSC at about 45° C. followed by one or more washes in 0.2×SSC with 0.1% SDS at 65° C., and preferably 4) very high stringency hybridization conditions are 0.5 M sodium phosphate with 7% SDS at 65° C. followed by one or more washes in 0.2×SSC with 1% SDS at 65° C. Very high stringency condition 4) is the appropriate condition and is the one that should be used unless otherwise specified.
[0090] It is understood that the molecules described herein may have additional conservative or non-essential amino acid substitutions, which have no substantial effect on their function.
[0091] The term "amino acid" is intended to encompass all molecules, whether natural or synthetic, that contain both amino and acid functional groups and can be included in a polymer of naturally occurring amino acids. Exemplary amino acids include naturally occurring amino acids, their analogs, derivatives, and congeners, amino acid analogs with variant side chains, and all stereoisomers of any of the foregoing. As used herein, the term "amino acid" includes both D- or L-optical isomers and peptidomimetics.
[0092] A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0093] The terms "polypeptide," "peptide," and "protein" (when single chain) are used interchangeably herein to refer to polymers of amino acids of any length. The polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The term also encompasses modified amino acid polymers, e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. Polypeptides may be isolated from natural sources, produced by recombinant techniques from eukaryotic or prokaryotic hosts, or may be the product of synthetic procedures.
[0094] As will be recognized by those skilled in the art, protein fragments, functional protein domains, and homologous proteins are also considered to be within the scope of the present invention.For example, provided herein is any protein fragment (meaning a polypeptide sequence of at least one amino acid residue shorter than the reference polypeptide sequence but otherwise identical) of a reference protein that is 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or more than 100 amino acids long.In another example, any protein that includes a stretch of about 20, about 30, about 40, about 50, or about 100 amino acids that is about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, or about 100% identical to any sequence described herein can be utilized according to the present invention. In one embodiment, a protein sequence utilized in accordance with the present disclosure contains 2, 3, 4, 5, 6, 7, 8, 9, 10 or more mutations as set forth in any of the sequences provided or referenced herein.
[0095] The terms "nucleic acid", "nucleic acid sequence", "nucleotide sequence", or "polynucleotide sequence", and "polynucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. A polynucleotide may be either single-stranded or double-stranded, and if single stranded, may be the coding strand or the non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. A nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin that does not occur in nature or is linked to another polynucleotide in a non-natural configuration.
[0096] As used herein, the term "isolated" refers to material that is removed from its original or natural environment (e.g., the natural environment, if it occurs in nature). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but an identical polynucleotide or polypeptide that has been separated by human intervention from some or all of the existing materials in a natural system is isolated. Such a polynucleotide may be part of a vector, and / or such a polynucleotide or polypeptide may be part of a composition, and still be isolated in that it is not part of the environment in which such a vector or composition is found in nature.
[0097] As used herein, the term "treatment" of a disorder, e.g., myeloma, means that a subject (e.g., a human) having a disorder, e.g., myeloma, and / or experiencing symptoms of a disorder, e.g., myeloma, experiences less severe symptoms and / or recovers more quickly when the antibody molecule is administered than when the antibody molecule is administered. In one embodiment, when myeloma is treated, a bone marrow biopsy shows fewer clonal plasma cells after effective treatment for myeloma. For example, a diagnostic assay detects fewer clonal plasma cells in a biological sample of a subject after administration of an antibody molecule described herein for effective treatment of myeloma. Other assays, urine tests, or blood tests can be used to monitor treatment in a patient or detect the presence, e.g., reduced presence (or absence), of symptoms of myeloma after treatment of myeloma in a subject. In one embodiment, when myeloma is treated, the level of β2 microglobulin (β2M) in serum or urine is reduced after effective treatment for myeloma. Treatment can, for example, partially or completely, alleviate, ameliorate, mitigate, inhibit, or reduce the manifestation of one or more of the effects or symptoms, characteristics, and / or causes of a disorder, such as, for example, myeloma, and / or reduce the incidence and optionally delay the onset. In one embodiment, treatment is treatment of a subject who does not show specific signs of a disorder, such as, for example, myeloma, and / or who shows only early signs of a disorder, such as, for example, nephropathy. In one embodiment, treatment is treatment of a subject who shows one or more established signs of a disorder, such as, for example, myeloma. In one embodiment, treatment is treatment of a subject who has been diagnosed with a disorder, such as, for example, myeloma.
[0098] As used herein, the term "preventing" a disorder, such as, for example, myeloma, means that a subject (e.g., a human) is less likely to have a disorder, such as, for example, myeloma, when receiving the antibody molecule.
[0099] Various aspects of the compositions and methods herein are described in further detail below. Additional definitions are set forth throughout the specification.
[0100] IL-2 drugs The present disclosure provides IL-2 agents, including, but not limited to, IL-2 variants, IL-2 fusion proteins, IL-2 complexes, and IL-2 conjugates. For example, the IL-2 agents described herein can have one or more structural and / or functional properties described herein. In one embodiment, the IL-2 agent comprises an IL-2 variant comprising one or more amino acid modifications (e.g., substitutions) described herein. In one embodiment, the IL-2 agent comprises an IL-2 variant comprising one or more amino acid modifications (e.g., substitutions) described in Table 9. In one embodiment, the IL-2 agent comprises an IL-2 variant comprising an amino acid sequence described in Table 9, or a portion thereof, or a portion thereof. In one embodiment, the IL-2 agent, or a portion thereof, is encoded by a nucleic acid comprising a nucleotide sequence described herein, e.g., a nucleotide sequence described in Table 10. The one or more amino acid modifications (e.g., substitutions), alone or in combination, can confer one or more desired biological properties described herein. In one embodiment, the IL-2 agent can modulate (e.g., increase) the proliferation, survival, activation, and / or function of Tregs. In one embodiment, the modulation is selective or specific for Treg. For example, an IL-2 agent can modulate the activity in Treg, but has limited or no ability to promote the activity in non-regulatory T cells. In one embodiment, the IL-2 agent comprises a polypeptide (also referred to herein as an IL-2 polypeptide agent).
[0101] IL-2 variants In one embodiment, the IL-2 agent comprises an IL-2 variant, eg, an IL-2 variant described herein.
[0102] In one embodiment, the IL-2 variant comprises an IL-2 polypeptide described herein (e.g., a human IL-2 polypeptide), or a functional fragment thereof. In one embodiment, the IL-2 variant comprises one or more amino acid modifications (e.g., substitutions) described in Table 9. In one embodiment, the IL-2 variant comprises or consists of an amino acid sequence described in Table 9, or a functional fragment thereof. In one embodiment, the IL-2 variant is encoded by a nucleic acid comprising a nucleotide sequence described herein, e.g., a nucleotide sequence described in Table 10.
[0103] Without wishing to be bound by theory, in one embodiment, it is believed that IL-2 variants described herein that have reduced human CD25 and / or reduced human CD122 / CD132 binding affinity compared to wild-type human IL-2 or an IL-2 reference IL-2 variant may have improved potency and / or selectivity for binding to and activating regulatory T cells (Tregs) over wild-type IL-2 or other IL-2 variants. The IL-2 variants described herein can be identified, for example, by screening a library of mutant IL-2 polypeptides to identify IL-2 variants that have binding affinity for human CD25 and / or human CD122 / CD132 in the desired range.
[0104] In one embodiment, the IL-2 variant has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more) properties, e.g., different and / or improved properties, described herein, compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant includes one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions) that provide different and / or improved properties compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all) of the following different and / or improved properties (e.g., as determined by the assays described herein) compared to wild-type IL-2 or a reference IL-2 variant: i) altering (e.g., enhancing or increasing) expression in vitro and / or in vivo; ii) altering (e.g., reducing or decreasing) aggregation in vitro and / or in vivo; iii) altering (e.g., enhancing or increasing) stability in vitro and / or in vivo; iv) modifying (e.g., enhancing or increasing) half-life in vitro and / or in vivo; v) altering (e.g., reducing or decreasing) turnover and / or clearance in vivo; vi) modifying (e.g., reducing or decreasing) susceptibility to proteolysis in vitro and / or in vivo; vii) altering (e.g., enhancing or increasing) resistance to proteolysis in vitro and / or in vivo; viii) altering (e.g., reducing or decreasing) the binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; ix) altering (e.g., reducing or decreasing) the binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; x) modifying (e.g., reducing or decreasing) the binding ability and / or binding affinity to the dimeric IL-2 receptor comprising human CD122 and human CD132 in vitro and / or in vivo; xi) altered (e.g., enhanced, increased, reduced, diminished, and / or selective) binding to Tregs in vitro and / or in vivo; xii) altered (e.g., enhanced, increased, reduced, diminished, and / or selective) activation of the IL-2 signaling pathway in Tregs in vitro and / or in vivo; xiii) Altering (e.g., enhancing, increasing, reducing, diminishing, and / or selectively) the ability to induce or promote Treg expansion, activity, survival, and / or proliferation in vitro and / or in vivo.
[0105] In one embodiment, the IL-2 variant has altered (e.g., enhanced or increased) expression in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased expression (e.g., in bacterial or mammalian cells) compared to wild-type IL-2. In one embodiment, the IL-2 variant has enhanced or increased expression (e.g., in bacterial or mammalian cells) compared to a reference IL-2 variant. In one embodiment, expression of the IL-2 variant is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, expression of the IL-2 variant is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 variant is expressed at a higher or increased level in vitro and / or in vivo, e.g., by about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, as determined by an assay of protein concentration. In one embodiment, the IL-2 variant is expressed at a higher or increased level, e.g., about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more increase, as determined, e.g., by an assay of protein concentration, compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant.
[0106] In one embodiment, the IL-2 variant has altered (e.g., reduced or decreased) aggregation in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has reduced or decreased aggregation compared to wild-type IL-2. In one embodiment, the IL-2 variant has reduced or decreased aggregation compared to a reference IL-2 variant. In one embodiment, aggregation of the IL-2 variant is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, aggregation of the IL-2 variant is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein aggregates at a lower or reduced level in vitro and / or in vivo, e.g., by about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, as determined, e.g., by melting temperature analysis (e.g., using fluorimetry), dynamic light scattering, and / or size exclusion chromatography, compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein aggregates at a lower or reduced level, e.g., about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more, as compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, e.g., as determined by melting temperature analysis (e.g., using fluorescence measurements), dynamic light scattering, and / or size exclusion chromatography.
[0107] In one embodiment, the IL-2 variant has altered (e.g., enhanced or increased) stability in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased stability compared to wild-type IL-2. In one embodiment, the IL-2 variant has enhanced or increased stability compared to a reference IL-2 variant. In one embodiment, the stability of the IL-2 variant is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the stability of the IL-2 variant is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein has enhanced or increased stability in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79 ...9%, about 79%, about 79%, about 7 An increase of 0%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or, for example, an increase of about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0108] In one embodiment, the IL-2 variant has an altered (e.g., enhanced or increased) half-life in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has an enhanced or increased half-life compared to wild-type IL-2. In one embodiment, the IL-2 variant has an enhanced or increased half-life compared to a reference IL-2 variant. In one embodiment, the half-life of the IL-2 variant is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the half-life of the IL-2 variant is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein has an enhanced or increased half-life in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 105%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 210%, about 220%, about 230%, about 240%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, about 500%, about 500%, about 510%, about 520%, about 530%, about 540%, about 550%, about 560%, about 570%, about 580%, about 590%, about 600%, about 610%, about 620%, about 630%, about 640%, about 650%, about 660%, about 670 An increase of 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or greater than, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0109] In one embodiment, the IL-2 variant has altered (e.g., reduced or decreased) turnover in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has reduced or decreased turnover compared to wild-type IL-2. In one embodiment, the IL-2 variant has reduced or decreased turnover compared to a reference IL-2 variant. In one embodiment, the turnover of the IL-2 variant is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the turnover of the IL-2 variant is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein has a lower, reduced, or decreased rate or level of turnover and / or clearance in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 82%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, A decrease of about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or a decrease of, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0110] In one embodiment, the IL-2 has an altered (e.g., reduced or decreased) susceptibility to proteolysis in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has reduced or decreased susceptibility to proteolysis compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 variant has reduced or decreased susceptibility to proteolysis compared to a reference IL-2 variant. In one embodiment, the susceptibility of the IL-2 variant to proteolysis is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the susceptibility of the IL-2 variant to proteolysis is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0111] In one embodiment, the IL-2 variant has an altered (e.g., enhanced or increased) resistance to proteolysis in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has an enhanced or increased resistance to proteolysis compared to wild-type IL-2. In one embodiment, the IL-2 variant has an enhanced or increased resistance to proteolysis compared to a reference IL-2 variant. In one embodiment, the resistance of the IL-2 variant to proteolysis is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the resistance of the IL-2 variant to proteolysis is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0112] In one embodiment, the IL-2 variant has an altered (e.g., reduced or decreased) binding ability and / or binding affinity to human CD25 in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has a reduced or decreased binding ability and / or binding affinity to human CD25 compared to wild-type human IL-2. In one embodiment, the IL-2 variant has a reduced or decreased binding ability and / or binding affinity to human CD25 compared to a reference IL-2 variant. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to human CD25 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to human CD25 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein has a reduced or decreased binding affinity to CD25 (e.g., human CD25), e.g., by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 7 A decrease of 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or a decrease of, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0113] In one embodiment, the IL-2 variant is, for example, about 5 to 500 pM, e.g., about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 100 pM, e.g., about 5 to 500 pM, e.g., about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95 ... to 500 pM, e.g., about 5 to 500 pM, e.g., about 5 to 500 pM, e.g., about 5 to 500 pM, e.g., about 5 to 500 pM, e.g., about 5 to 500 pM, e.g., about 5 to 500 p , about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 200, 250, about 300, about 350, about 400, about 450, or about 500 pM, or, for example, about 10 to about 400 pM, about 20 to about 300 pM, about 50 to about 200 pM, about 100 to about 150 pM, about 5 to about 10 pM, for example, about 10 to about 20 pM, about 20 to about 30 pM, or about 30 to about 40 pM, e.g. For example, about 40 to about 50 pM, about 50 to about 60 pM, about 60 to about 70 pM, about 70 to about 80 pM, about 80 to about 90 pM, about 90 to about 100 pM, about 100 to about 110 pM, about 110 to about 120 pM, about 120 to about 130 pM, about 130 to about 140 pM, about 140 to about 150 pM, about 150 to about 200 pM, about 200 to about 250 pM, about 250 to about 300 pM, about 300 to about 350 pM, about 350 to about 400 pM, about 400 to about A dissociation constant (K) of 500 pM or, for example, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 200, about 250, about 300, about 350, about 400, about 450, or greater than about 500 pM. D ) and binds to CD25 (e.g., human CD25) with low affinity.
[0114] In one embodiment, the IL-2 variant has a cytoplasmic affinity of, for example, about 0.1 to 10 nM, e.g., about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 6, about 7, about 8, about 9, or about 10 nM, or for example, about 0.2 to about 5 nM, about 0.5 to about 2 nM, about 1 to 1.5 nM, about 0.1 to about 0.2 nM, e.g., about 0.2 to about 0.3 nM, about 0.3 to about 0.4, as determined, for example, by surface plasmon resonance (e.g., Biacore) and / or biolayer interferometry (e.g., Octet binding). nM, or about 0.4 to about 0.5 nM, for example, about 0.5 to about 0.6 nM, about 0.6 to about 0.7 nM, about 0.7 to about 0.8 nM, about 0.8 to about 0.9 nM , about 0.9 to about 1 nM, about 1 to about 1.5 nM, about 1.5 to about 2 nM, about 2.5 to about 3 nM, about 3.5 to about 4 nM, about 4 to about 4.5 nM, about 4.5 to about 5 nM , about 5 to about 6 nM, about 6 to about 7 nM, about 7 to about 8 nM, about 8 to about 9 nM, or about 9 to about 10 nM, or for example, about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 nM or more. D ) and binds to CD25 (e.g., human CD25) with low affinity.
[0115] In one embodiment, the IL-2 variant has an altered (e.g., reduced or decreased) binding ability and / or binding affinity to human CD132 in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has a reduced or decreased binding ability and / or binding affinity to human CD132 compared to wild-type IL-2. In one embodiment, the IL-2 variant has a reduced or decreased binding ability and / or binding affinity to human CD132 compared to a reference IL-2 variant. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to human CD132 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to human CD132 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0116] In one embodiment, the IL-2 variant has a binding capacity and / or binding affinity to the human dimeric IL-2 receptor comprising human CD122 and human CD132 that is altered (e.g., reduced or decreased) in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has a reduced or decreased binding capacity and / or binding affinity to the human dimeric IL-2 receptor comprising human CD122 and human CD132 compared to wild-type IL-2. In one embodiment, the IL-2 variant has a reduced or decreased binding capacity and / or binding affinity to the human dimeric IL-2 receptor comprising human CD122 and human CD132 compared to a reference IL-2 variant. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to a human dimeric IL-2 receptor comprising human CD122 and human CD132 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to a human dimeric IL-2 receptor comprising human CD122 and human CD132 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0117] In one embodiment, the IL-2 variant has a reduced or decreased binding affinity to the CD122 / CD132 heterodimer (e.g., human CD122 / CD132 heterodimer), e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49 ... A decrease of about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or a decrease of, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0118] In one embodiment, the IL-2 variant is, for example, at about 0.2 to 20 nM, e.g., about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about ... to 20 nM, e.g., about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 1 0 nM, or, for example, about 0.5 to about 15 nM, about 1 to about 10 nM, about 2 to about 5 nM, about 0.2 to about 0.3 nM, about 0.3 to about 0.4 nM, about 0.4 to about 0.5 nM, about 0.5 to about 0.6 nM, about 0.6 to about 0.7 nM, about 0.7 to about 0.8 nM, about 0.8 to about 0.9 nM, about 0.9 to about 1 nM, about 1 to about 1.1 nM, about 1.1 to about 1.2 nM, about 1.2 to about 1.3 nM, about 1.3 to about 1.4 nM, about 1.4 to about 1.5 nM, about 1.5 to about 2 nM, about 2 to about 3 nM, about 3 to about 4 nM, about 4 to about 5 nM, about 5 to about 6 nM, about 6 to about 7 nM, about 7 to about 8 nM, about 8 to about 9 nM, about 9 to about 10 nM, about 10 to about 11 nM, about 11 to about 12 nM, about 12 to about 13 nM, about 13 to about 14 nM, about 14 to about 15 nM, about 15 to about 16 nM, about 16 to about 17 nM, about 17 to about 18 nM, about 18 to about 19 nM, or about 19 to about 20 nM, or for example, about 0.2, about 0. about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about 20 nM.
[0119] In one embodiment, the IL-2 variant has a cytoplasmic affinity of, for example, about 0.2 to 300 nM, e.g., about 0.2 nM, about 0.5 nM, about 1 nM, about 2 nM, about 5 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 110 nM, about 120nM, about 130nM, about 140nM, about 150nM, about 160nM, about 170nM, about 180nM, about 190nM, about 200nM, about 210nM, about 220nM, about 230nM, about 240nM, about 250nM, about 260nM, about 270nM, about 280nM, about 290nM, or about 300nM, or for example, about 0.5 to about 15nM, about 1 to about 10nM, about 2 to about 5nM, about 0.2nM to about 0.5nM, about 0.5nM to about 1nM, about 1 to about 2nM, about 2nM to about 5nM, about 5nM M ~ about 10nM, about 10nM to about 15nM, about 15nM to about 20nM, about 20nM to about 25nM, about 25 to about 30nM, about 30nM to about 40nM, about 40nM to about 50nM, about 50 to about 60nM, about 60 to about 70nM, about 70nM to about 80n M, about 80nM to about 90nM, about 90nM to about 100nM, about 100nM to about 110nM, about 110nM to about 120nM, about 120nM to about 130nM, about 130nM to about 140nM, about 140nM to about 150nM, about 150nM to about 160n M, about 160 nM to about 170 nM, about 170 nM to about 180 nM, about 180 nM to about 190 nM, about 190 nM to about 200 nM, about 200 nM to about 210 nM, about 210 nM to about 220 nM, about 220 nM to about 230 nM, about 230 nM to about 240 nM, about 240 nM to about 250 nM, about 250 nM to about 260 nM, about 260 nM to about 270 nM, about 270 nM to about 280 nM, about 280 nM to about 290 nM, or about 290 nM to about 300 nM, or for example, greater than about 0.2, about 0.5, about 1, about 2, about 5, about 10, about 15, about 20nM, about 25nM, about 30nM, about 40nM, about 50nM, about 60nM, about 70nM, about 80nM, about 90n M, about 100nM, about 110nM, about 120nM, about 130nM, about 140nM, about 150nM, about 160nM, about 170nM, about 180nM, about 190nM, It binds to low affinity CD122 / CD132 heterodimers (e.g., human CD122 / CD132 heterodimers) with a dissociation constant (KD) of greater than about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 260 nM, about 270 nM, about 280 nM, about 290 nM, or about 300 nM.
[0120] In one embodiment, the IL-2 variant has altered (e.g., enhanced, increased and / or selective) binding to Tregs in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased binding to Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has selective binding to Tregs compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 variant has enhanced or increased binding to Tregs compared to a reference IL-2 variant. In one embodiment, the IL-2 variant has selective binding to Tregs compared to a reference IL-2 variant. In one embodiment, binding to Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, binding to Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0121] In one embodiment, the IL-2 variant has altered (e.g., enhanced, increased and / or selective) activation of the IL-2 signaling pathway in Tregs in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased activation of the IL-2 signaling pathway in Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has selective activation of the IL-2 signaling pathway in Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has enhanced or increased activation of the IL-2 signaling pathway in Tregs compared to a reference IL-2 variant. In one embodiment, the IL-2 variant has selective activation of the IL-2 signaling pathway in Tregs compared to a reference IL-2 variant. In one embodiment, activation of the IL-2 signaling pathway in Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, activation of the IL-2 signaling pathway in Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0122] In one embodiment, the IL-2 variant has, e.g., about 1, about 2, about 3, about 4, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 6 Selectively activates IL-2 signaling in T regulatory cells in vitro and / or in vivo having a T helper EC50 / Treg EC50 ratio of greater than 4, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, or about 3000 or more.
[0123] In one embodiment, the IL-2 variant has a IL-2 activity greater than or equal to about 1, about 2, about 3, about 4, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 20 00, 2500, or greater than about 3000 or more, or for example, 1 and greater than about 1-2, about 2-3, about 3-4, about 4-5, 1 to greater than about 1-10, 1 and greater than about 1-20, 1 to greater than about 1-30, 1 and greater than about 1-40, 1 and greater than about 1-50, about 2-10, about 2-20, about 2-30, about 2-40, 2-50, about 5-10, about Selectively activates IL-2 signaling in T regulatory cells in vitro and / or in vivo having an NK cell EC50 / Treg EC50 ratio of 5-20, about 5-30, about 5-40, about 5-50, about 10-20, about 10-30, about 10-40, about 10-50, about 20-40, about 20-50, about 50-100, about 100-200, about 200-500, about 500-1000, about 1000-2000, or about 1000-3000.
[0124] In one embodiment, the IL-2 variant has an altered (e.g., enhanced, increased and / or selective) ability to induce or promote expansion, activity, survival and / or proliferation of Tregs in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has an enhanced or increased ability to induce or promote expansion, activity, survival and / or proliferation of Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant had a selective ability to induce or promote expansion, activity, survival and / or proliferation of Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has an enhanced or increased ability to induce or promote expansion, activity, survival and / or proliferation of Tregs compared to a reference IL-2 variant. In one embodiment, the IL-2 variant had a selective ability to induce or promote expansion, activity, survival and / or proliferation of Tregs compared to a reference IL-2 variant. In one embodiment, the ability to induce or promote Treg expansion, activity, survival, and / or proliferation is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the ability to induce or promote Treg expansion, activity, survival, and / or proliferation is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0125] In one embodiment, the IL-2 variant has enhanced or increased potency and / or ability to induce or promote T regulatory cell activity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 105%, about 100%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, about 120%, about 122%, about 123%, about 124%, about 125%, about 126%, about 127%, about 128%, about 129%, about 130%, about 131%, about 132%, about 133%, about 134%, about 135%, about 136%, about 137%, about 138%, about 140%, about 142%, about 144%, about 145%, about 146%, about 147%, about 148%, about 149%, about 150%, about 151%, about 152%, about 153%, about 154%, about 155%, about 156%, about 157%, about 158%, about 159%, about 160%, about 161%, about 162%, about 163%, about 164%, about 165%, about 166%, about or has an EC50 against Treg that is reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0126] In one embodiment, the IL-2 variant has a reduced or diminished potency and / or ability to induce or promote T regulatory cell activity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95 ... 0%, about 85%, about 90%, about 95%, about 100% or more higher, or reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold, about 50-fold, about 100-fold, about 200-fold, about 500-fold, about 1000-fold, about 2000-fold, about 5000-fold, about 10,000-fold, about 15,000-fold, about 20,000-fold or more.
[0127] In one embodiment, the T helper cells described herein are CD45+CD3+CD4+Foxp3- cells, e.g., as determined by flow cytometry. In one embodiment, the Tregs described herein are CD45+CD3+CD4+Foxp3+ cells, e.g., as determined by flow cytometry. In one embodiment, the NK cells described herein are CD45+CD3- cells that are CD56+ and / or CD16+, e.g., as determined by flow cytometry. In one embodiment, the NK cells described herein are CD45+CD3-CD56+ cells, e.g., as determined by flow cytometry.
[0128] In one embodiment, an IL-2 variant has one or more of the same, or substantially the same, structural and / or functional properties as wild-type IL-2 or a reference IL-2 variant.
[0129] In one embodiment, the reference IL-2 variant comprises an amino acid sequence having about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an IL-2 variant described herein. In one embodiment, the reference IL-2 variant comprises the amino acid sequence of SEQ ID NO:1 (IL-2 C125S). In one embodiment, the IL-2 variant comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:1 and includes one or more (2, 3, 4, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions) described herein.
[0130] For purposes of this disclosure, IL-2 variant position numbering begins with the first amino acid following the signal peptide of an exemplary wild-type (WT) human IL-2 polypeptide. MYRMQLLSCIALSLALVTNS / A1 / P2 / T3 / S4 / S5 / S6 / T7 / K8 / K9 / T10 / Q11 / L12 / Q13 / L14 / E15 / H16 / L17 / L18 / L19 / D20 / L21 / Q22 / M23 / I24 / L25 / N26 / G27 / I28 / N29 / N30 / Y31 / K32 / N33 / P34 / K35 / L36 / T37 / R38 / M39 / L40 / T41 / F42 / K43 / F44 / Y45 / M46 / P47 / K48 / K49 / A50 / T51 / E52 / L53 / K54 / H55 / L5 6 / Q57 / C58 / L59 / E60 / E61 / E62 / L63 / K64 / P65 / L66 / E67 / E68 / V69 / L70 / N71 / L72 / A73 / Q7 4 / S75 / K76 / N77 / F78 / H79 / L80 / R81 / P82 / R83 / D84 / L85 / I86 / S87 / N88 / I89 / N90 / V91 / I 92 / V93 / L94 / E95 / L96 / K97 / G98 / S99 / E100 / T101 / T102 / F103 / M104 / C105 / E106 / Y107 / A 108 / D109 / E110 / T111 / A112 / T113 / I114 / V115 / E116 / F117 / L118 / N119 / R120 / W121 / I122 / T123 / F124 / C125 / Q126 / S127 / I128 / I129 / S130 / T131 / L132 / T133 (SEQ ID NO: 360, Uniprot P60568, signal peptide Underlined The corresponding amino acid sequence without the signal peptide is shown in SEQ ID NO:1031.
[0131] In one embodiment, the IL-2 agent contains amino acid modifications (eg, substitutions) at positions corresponding to human IL-2 (eg, contains the amino acid sequence of SEQ ID NO: 1031).
[0132] In one embodiment, the IL-2 variant is A1 / P2 / X3 / S4 / S5 / S6 / T7 / K8 / K9 / T10 / Q11 / L12 / Q13 / L14 / E15 / X16 / L17 / L18 / L19 / D20 / L21 / Q22 / M23 / I24 / L25 / N26 / G27 / X28 / N29 / N30 / Y31 / K32 / N33 / P34 / X35 / L36 / T37 / X38 / M39 / L40 / T41 / X42 / K43 / F44 / Y45 / M46 / P47 / K48 / K49 / A50 / T51 / E52 / L53 / K 54 / H55 / L56 / Q57 / C58 / L59 / E60 / E61 / E62 / L63 / K64 / P65 / L66 / E67 / X68 / X69 / L70 / N71 / L72 / A73 / X74 / S75 / K76 / N77 / F78 / H79 / L80 / R81 / P82 / R83 / X84 / L85 / I86 / X87 / X88 / I89 / N90 / V9 1 / X92 / V93 / L94 / E95 / L96 / K97 / G98 / S99 / E100 / T101 / T102 / F103 / M104 / C105 / E106 / Y107 / A 108 / D109 / E110 / T111 / A112 / T113 / I114 / V115 / E116 / F117 / L118 / N119 / R120 / W121 / I122 / T123 / F124 / X125 / X126 / S127 / I128 / I129 / S130 / T131 / L132 / T133 (SEQ ID NO: 1032),
[0133] wherein X3 is T or A, X16 is H, L or N, X28 is I, T or F, X35 is K or E, X38 is R, E, N or Q, X42 is F, A, K or Q, X68 is E, Q or N, X69 is V or A, X74 is Q or P, X84 is D or V, X87 is S or R, X88 is N, D, L or S, X92 is I or S, X125 is C or S, and X126 is Q, K, R or T, provided that the IL-2 variant does not comprise the amino acid sequence of SEQ ID NO: 1 or 1031. In one embodiment, the IL-2 variant comprises or consists of an IL-2 variant amino acid sequence described herein.
[0134] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all) of the positions described herein. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all) of the positions selected from T3, H16, I28, K35, R38, F42, E68, V69, Q74, D84, S87, N88, I92, C125, or Q126.
[0135] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position T3. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position H16. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position I28. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position K35. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position R38. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position F42. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position E68. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position V69. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position Q74. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position D84. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position S87. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position N88. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position I92. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position C125. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position Q126.
[0136] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at positions V69, Q74, or a combination thereof. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at positions V69 and Q74. In one embodiment, the IL-2 variant comprises the amino acid substitution V69A. In one embodiment, the IL-2 variant comprises the amino acid substitution Q74P.
[0137] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position H16, I92, D84, or a combination thereof. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position H16, optionally the amino acid substitution is H16N, H16L, or H16D. In one embodiment, the IL-2 variant comprises the amino acid substitution H16N. In one embodiment, the IL-2 variant comprises the amino acid substitution H16L. In one embodiment, the IL-2 variant comprises the amino acid substitution H16D.
[0138] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position 192, optionally, the amino acid substitution is 192S. In one embodiment, the IL-2 variant comprises the amino acid substitution 192S.
[0139] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position D84, optionally, the amino acid substitution is D84V. In one embodiment, the IL-2 variant comprises the amino acid substitution D84V.
[0140] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position K35, R38, F42, E68, or a combination thereof. In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position K35, optionally the amino acid substitution is K35E. In one embodiment, the IL-2 variant comprises the amino acid substitution K35E.
[0141] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position R38, optionally the amino acid substitution is R38E, R38N or R38Q. In one embodiment, the IL-2 variant comprises the amino acid substitution R38N. In one embodiment, the IL-2 variant comprises the amino acid substitution R38Q.
[0142] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position F42, optionally the amino acid substitution is F42K or F42Q. In one embodiment, the IL-2 variant comprises the amino acid substitution F42K. In one embodiment, the IL-2 variant comprises the amino acid substitution F42Q.
[0143] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at one, two, or all of: (i) (a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35, and (ii) positions H16, I92, or D84. In one embodiment, the IL-2 variant further comprises an amino acid modification (e.g., substitution) at one, two, or all of positions R38, F42, or E68.
[0144] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at: (i) (a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35, and (ii) (a) one, two, or all of positions H16, I92, or D84, or (b) one, two, or all of positions R38, F42, or E68.
[0145] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at: (i) (a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35, and (ii) (a) one, two, or all of positions H16, I92, or D84, and (b) one, two, or all of positions R38, F42, or E68.
[0146] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and H16, optionally the amino acid substitutions are V69A, Q74P and H16N or H16L, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and H16N or H16L. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and H16N. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and H16N. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and H16L.
[0147] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, and I92, optionally the amino acid substitutions are V69A, Q74P, and I92S, respectively. In one embodiment, the IL-2 variant comprises the amino acid substitutions V69A, Q74P, and I92S.
[0148] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, and D84, optionally the amino acid substitutions are V69A, Q74P, and D84V, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and D84V.
[0149] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and R38, optionally the amino acid substitutions are V69A, Q74P and R38Q, respectively. In one embodiment, the IL-2 variant comprises the amino acid substitutions V69A, Q74P, and R38Q.
[0150] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and F42, optionally the amino acid substitutions are V69A, Q74P and F42Q, respectively. In one embodiment, the IL-2 variant comprises the amino acid substitutions V69A, Q74P, and F42Q.
[0151] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and R38, optionally the amino acid substitutions are V69A, Q74P and R38N, respectively. In one embodiment, the IL-2 variant comprises the amino acid substitutions V69A, Q74P, and R38N.
[0152] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and R38, optionally the amino acid substitutions are V69A, Q74P and R38E, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and R38E.
[0153] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, K35 and H16, optionally the amino acid substitutions are V69A, Q74P, K35E and H16N, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, K35E and H16N.
[0154] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, K35, H16 and R38, optionally the amino acid substitutions are V69A, Q74P, K35E, H16N and R38N, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, K35E, H16N and R38N.
[0155] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, H16 and R38, optionally the amino acid substitutions are V69A, Q74P, H16N and R38N or R38Q, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, H16N and R38N or R38Q. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, H16N and R38N. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, H16N and R38N. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, H16N and R38Q.
[0156] In one embodiment, the IL-2 variant comprises an amino acid modification (eg, a substitution) at position I28, E68, S87, N88, Q126, or a combination thereof.
[0157] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position I28, optionally the amino acid substitution is I28T and I28F. In one embodiment, the IL-2 variant comprises the amino acid substitution I28T. In one embodiment, the IL-2 variant comprises the amino acid substitution I28F.
[0158] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position E68, optionally the amino acid substitution is E68Q or E68N. In one embodiment, the IL-2 variant comprises the amino acid substitution E68Q. In one embodiment, the IL-2 variant comprises the amino acid substitution E68N.
[0159] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position S87, optionally, the amino acid substitution is S87 R. In one embodiment, the IL-2 variant comprises the amino acid substitution S87R.
[0160] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position N88, optionally the amino acid substitution is N88S, N88L, or N88D. In one embodiment, the IL-2 variant comprises the amino acid substitution N88S, N88L, or N88D. In one embodiment, the IL-2 variant comprises the amino acid substitution N88S. In one embodiment, the IL-2 variant comprises the amino acid substitution N88L. In one embodiment, the IL-2 variant comprises the amino acid substitution N88D.
[0161] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position Q126, optionally the amino acid substitution is Q126T, Q126K, or Q126R. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126T, Q126K, or Q126R. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126T, Q126K, or Q126R. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126T. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126K. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126R.
[0162] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position C125, optionally the amino acid substitution is C125S. In one embodiment, the IL-2 variant comprises the amino acid substitution C125S.
[0163] In one embodiment, the IL-2 variant comprises an amino acid modification (e.g., substitution) at position T3, optionally the amino acid substitution is T3A. In one embodiment, the IL-2 variant comprises the amino acid substitution T3A.
[0164] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and C125, optionally the amino acid substitutions are V69A, Q74P and C125S, respectively. In one embodiment, the IL-2 variant comprises the amino acid substitutions V69A, Q74P, and C125S.
[0165] In one embodiment, the IL-2 variant comprises an amino acid modification (eg, substitution) at positions T3, H16, I92, or a combination thereof, optionally, the amino acid substitutions are T3A, H16N, and I92S, respectively.
[0166] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions H16, V69, Q74 and C125, optionally the amino acid substitutions are H16N, V69A, Q74P and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16N, V69A, Q74P, and C125S.
[0167] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions H16, V69, Q74 and C125, optionally the amino acid substitutions are H16L, V69A, Q74P and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16L, V69A, Q74P, and C125S.
[0168] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions H16, V69, Q74, I92 and C125, optionally the amino acid substitutions are H16L, V69A, Q74P, I92S and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16L, V69A, Q74P, I92S and C125S.
[0169] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions T3, V69, Q74 and C125, optionally the amino acid substitutions are T3A, V69A, Q74P and C125S, respectively. In one embodiment, the IL-2 variant comprises the amino acid substitutions T3A, V69A, Q74P, and C125S.
[0170] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions T3, H16, V69, Q74, and C125, optionally the amino acid substitutions are T3A, H16N or H16L, V69A, Q74P, and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, H16N, V69A, Q74P, and C125S. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, H16L, V69A, Q74P, and C125S.
[0171] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions T3, V69, Q74, I92 and C125, optionally the amino acid substitutions are T3A, V69A, Q74P, I92S and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, V69A, Q74P, I92S and C125S. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, V69A, Q74P, I92S and C125S.
[0172] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions H16, K35, V69 and Q74, optionally the amino acid substitutions are H16L, K35E, V69A and Q74P, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16L, K35E, V69A, and Q74P.
[0173] In one embodiment, the IL-2 variant comprises amino acid modifications (e.g., substitutions) at positions H16, R38, V69A and Q74P, optionally the amino acid substitutions are H16L, R38Q, V69A and Q74P, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16L, R38Q, V69A and Q74P.
[0174] In one embodiment, the IL-2 variant comprises the amino acid substitutions H16L, V69A, Q74P, and C125S. In one embodiment, the IL-2 variant comprises the amino acid substitutions H16N, V69A, Q74P, and C125S.
[0175] There are various technical effects associated with the presence of a set of mutations comprising an amino acid substitution at position H16 in combination with a particular set of mutations described herein, for example, amino acid substitutions at positions V69, Q74, and C125 (e.g., H16L, V69A, Q74P, and C125S). Without wishing to be bound by theory, in one embodiment, IL-2 variants comprising the aforementioned mutations also reduce binding affinity to CD122 and / or CD132, which is believed to increase the potency and selectivity of the IL-2 variants for regulatory T cells (Tregs) compared to other T cell types. Without wishing to be bound by theory, in one embodiment, IL-2 variants comprising the aforementioned mutations are also believed to be significantly more stable, for example due to the presence of the stabilizing V69A and Q74P mutations. For example, it has been unexpectedly discovered that the V69A and Q74P substitutions do not substantially increase the binding affinity of IL-2 variants to CD25, but rather stabilize the IL-2 variants in an active conformation sufficient for binding to CD25. Thus, IL-2 variants containing these mutations selectively activate regulatory T cells (Tregs) and are significantly more stable. Without wishing to be bound by theory, in one embodiment, it is further believed that IL-2 variants containing the aforementioned mutations reduce or decrease the binding ability and / or binding affinity to CD25, improving the lifespan of the IL-2 variants. Without wishing to be bound by theory, in one embodiment, it is believed that IL-2 variants containing these mutations do not substantially promote the expansion, activation, survival, and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo. Without wishing to be bound by theory, in one embodiment, it is further believed that IL-2 variants comprising the aforementioned mutations have reduced imprecise disulfide pairing and improved stability, e.g., due to the presence of the C125S mutation. In one embodiment, IL-2 agents comprising the H16L mutation have reduced binding affinity to CD122 and / or CD132, and / or increased potency and selectivity for Tregs over other T cell types, compared to IL-2 agents comprising other H16 mutations.These properties make IL-2 variants containing these mutations particularly suitable for treating disorders and conditions resulting from an aberrant immune response.
[0176] Thus, in one embodiment, an IL-2 variant (e.g., an IL-2 variant or IL-2 fusion protein) comprising an amino acid substitution at position H16 (e.g., H16L, V69A, Q74P and C125S) in combination with amino acid substitutions at positions V69, Q74 and C125 has, inter alia, one or more (e.g., 2, 3, 4, 5, 6, 7 or all) of the following properties relative to a wild-type IL-2 or reference IL-2 variant that does not comprise the amino acid substitution: (i) enhanced or increased stability in vitro or in vivo, (ii) increased binding to human CD122 in vitro and / or in vivo. (iii) reduced or decreased binding ability and / or binding affinity to human CD132 in vitro and / or in vivo; (iv) reduced or decreased affinity of the IL-2 variant for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) reduced or decreased binding ability and / or binding affinity to human CD25 in vitro and / or in vivo; (vi) reduced or decreased binding ability and / or binding affinity to regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in T regulatory cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote Treg expansion, activity, survival and / or proliferation.
[0177] In one embodiment, the IL-2 variant is SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO: 35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:1000, SEQ ID NO:1001, SEQ ID NO:1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0178] In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 4, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO:5, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 variant comprises or consists of an amino acid sequence of SEQ ID NO: 1000, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.In one embodiment, the IL-2 variant comprises or consists of an amino acid sequence of SEQ ID NO: 1001, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 variant comprises or consists of an amino acid sequence of SEQ ID NO: 1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0179] In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001 or 1002, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 4 or 5, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 4, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 5, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 11, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1000, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1001, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1002, or a functional fragment thereof.
[0180] Without wishing to be bound by theory, in one embodiment, an IL-2 variant comprising or consisting of the amino acid sequence of SEQ ID NO:5 or a functional fragment thereof may have at least one or more of the following advantageous properties: (i) having a reduced binding affinity to CD122 and / or CD132, which increases the potency and selectivity of the IL-2 agent for regulatory T cells (Tregs) compared to other T cell types; (ii) being significantly more stable, e.g., due to the presence of stabilizing mutations V69A and Q74P; (iii) having a reduced or decreased binding capacity and / or binding affinity to CD25, which improves the longevity of the IL-2 agent; (iv) not substantially promoting the expansion, activity, survival and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo; and / or (v) having reduced and imprecise disulfide pairing and improved stability, e.g., due to the presence of a C125S mutation. In one embodiment, IL-2 agents comprising the H16L mutation have reduced binding affinity for CD122 and / or CD132, and / or increased potency and selectivity for Tregs over other T cell types, as compared to IL-2 agents comprising other H16 mutations. These properties make IL-2 variants comprising or consisting of the amino acid sequence of SEQ ID NO:5 particularly suitable for treating disorders and conditions resulting from aberrant immune responses.
[0181] Thus, in one embodiment, an IL-2 variant comprising, or consisting of, an amino acid sequence of SEQ ID NO:5 or a functional fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids, has, in particular, one or more (e.g., 2, 3, 4, 5, 6, 7, or all) of the following properties relative to wild-type IL-2 or a reference IL-2 variant that does not contain amino acid substitutions: (i) enhanced in vitro or in vivo stability. (ii) a reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iii) a reduced or decreased binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; (iv) a reduced or decreased affinity of the IL-2 variant for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) a reduced or decreased or substantially unchanged binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; (vi) a reduced or decreased binding capacity and / or binding affinity to regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in T regulatory cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote Treg expansion, activity, survival and / or proliferation.
[0182] As described herein, the present disclosure provides IL-2 fusion proteins, IL-2 complexes, and IL-2 conjugates comprising the IL-2 variants described herein. In one embodiment, one or more distinct and / or improved properties of the IL-2 variants described herein are maintained, transferred, or imparted to the IL-2 fusion protein, IL-2 complex, or IL-2. For purposes of this disclosure, the terms "IL-2 variant" and "IL-2 mutein" may be used interchangeably herein.
[0183] In one embodiment, the IL-2 variant comprises a polypeptide (also referred to herein as an "IL-2 variant polypeptide"). The present disclosure provides isolated nucleic acid molecules encoding the IL-2 variants described herein, as well as vectors and host cells thereof. Nucleic acid molecules include, but are not limited to, RNA, genomic DNA, and cDNA.
[0184] IL-2 fusion proteins In one embodiment, the IL-2 agent comprises an IL-2 fusion protein, such as an IL-2 fusion protein described herein.
[0185] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant, e.g., an IL-2 variant described herein. In one embodiment, the IL-2 fusion protein comprises one or more amino acid modifications (e.g., substitutions) described in Table 9. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence described in Table 9, or a functional fragment thereof. In one embodiment, the IL-2 variant is encoded by a nucleic acid comprising a nucleotide sequence described herein, e.g., a nucleotide sequence described in Table 10.
[0186] Without wishing to be bound by theory, in one embodiment, it is believed that IL-2 fusion proteins described herein that have reduced human CD25 and / or reduced human CD122 / CD132 binding affinity compared to an IL-2 fusion protein comprising wild-type human IL-2 or a reference IL-2 fusion protein may have improved potency and / or selectivity for binding to and activating regulatory T cells (Tregs) over IL-2 fusion proteins comprising wild-type human IL-2 or other IL-2 fusion proteins.
[0187] In one embodiment, the IL-2 fusion protein has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more) properties described herein, e.g., different and / or improved properties, as compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein includes one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions) that provide different and / or improved properties as compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all) properties described herein, e.g., the following different and / or improved properties (e.g., as determined by the assays described herein), as compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein: i) altering (e.g. enhancing or increasing) expression in vitro and / or in vivo; ii) altering (e.g., reducing or decreasing) aggregation in vitro and / or in vivo; iii) altering (e.g., enhancing or increasing) stability in vitro and / or in vivo; iv) modifying (e.g., enhancing or increasing) half-life in vitro and / or in vivo; v) altering (e.g., reducing or decreasing) turnover and / or clearance in vivo; vi) altering (e.g., reducing or decreasing) susceptibility to proteolysis in vitro and / or in vivo vii) altering (e.g., enhancing or increasing) resistance to proteolysis in vitro and / or in vivo; viii) altering (e.g., reducing or decreasing) the binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; ix) altering (e.g., reducing or decreasing) the binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; x) modifying (e.g., reducing or decreasing) the binding ability and / or binding affinity to the dimeric IL-2 receptor comprising human CD122 and human CD132 in vitro and / or in vivo; xi) altered (e.g., enhanced, increased, reduced, diminished, and / or selective) binding to Tregs in vitro and / or in vivo; xii) altered (e.g., enhanced, increased, reduced, diminished, and / or selective) activation of the IL-2 signaling pathway in Tregs in vitro and / or in vivo; xiii) Altering (e.g., enhancing, increasing, reducing, diminishing, and / or selectively) the ability to induce or promote Treg expansion, activity, survival, and / or proliferation in vitro and / or in vivo.
[0188] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced or increased) expression in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased expression (e.g., in bacterial or mammalian cells) compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has enhanced or increased expression (e.g., in bacterial or mammalian cells) compared to a reference IL-2 fusion protein. In one embodiment, the expression of the IL-2 fusion protein is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the expression of the IL-2 fusion protein is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein is expressed at a higher or increased level in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, compared to an IL-2 fusion protein comprising a wild-type IL-2 or a reference IL-2 fusion protein, as determined by an assay of protein concentration. In one embodiment, the IL-2 fusion protein is expressed at a higher or increased level, e.g., about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more increase, e.g., compared to an IL-2 fusion protein comprising a wild-type IL-2 or a reference IL-2 fusion protein, as determined, e.g., by an assay of protein concentration.
[0189] In one embodiment, the IL-2 fusion protein has altered (e.g., reduced or decreased) aggregation in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has reduced or decreased aggregation compared to wild-type IL-2. In one embodiment, the IL-2 fusion protein has reduced or decreased aggregation compared to a reference IL-2 fusion protein. In one embodiment, aggregation of the IL-2 fusion protein is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, aggregation of the IL-2 fusion protein is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein aggregates at a lower or reduced level in vitro and / or in vivo, e.g., by about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, compared to, e.g., an IL-2 fusion protein comprising wild-type IL-2, or a reference IL-2 fusion protein, as determined, e.g., by melting temperature analysis (e.g., using fluorimetry), dynamic light scattering, and / or size exclusion chromatography. In one embodiment, the IL-2 fusion protein aggregates at a lower or reduced level, e.g., about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more, as compared to, e.g., an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, as determined by, e.g., melting temperature analysis (e.g., using fluorimetry), dynamic light scattering, and / or size exclusion chromatography.
[0190] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced or increased) stability in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased stability compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has enhanced or increased stability compared to a reference IL-2 fusion protein. In one embodiment, the stability of the IL-2 fusion protein is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the stability of the IL-2 fusion protein is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein has enhanced or increased stability in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 210%, about 220%, about 230%, about 240%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, about 500%, about 510%, about 520%, about 530%, about 540%, about 550%, about 560%, about 570%, about 580%, about 590%, about 610%, about 620%, about 630%, about 640%, about 650%, about 660%, about 670%, about 680%, about 690%, about 700%, about 710%, about 720%, about 730 An increase of about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or, for example, an increase of about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0191] In one embodiment, the IL-2 fusion protein has an altered (e.g., enhanced or increased) half-life in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has an enhanced or increased half-life compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has an enhanced or increased half-life compared to a reference IL-2 fusion protein. In one embodiment, the half-life of the IL-2 fusion protein is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the half-life of the IL-2 fusion protein is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein has an enhanced or increased half-life in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, compared to an IL-2 fusion protein comprising a wild-type IL-2 or a reference IL-2 fusion protein, e.g., as determined by ELISA, flow cytometry and / or mass spectrometry. , about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0192] In one embodiment, the IL-2 fusion protein has altered (e.g., reduced or decreased) turnover in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has reduced or decreased turnover compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has reduced or decreased turnover compared to a reference IL-2 fusion protein. In one embodiment, the turnover of the IL-2 fusion protein is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the turnover of the IL-2 fusion protein is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein has a lower, reduced, or decreased rate or level of turnover and / or clearance in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 35%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 120%, about 140%, about 160%, about 180%, about 200%, about 220%, about 240%, about 260%, about 280%, about 300%, about 350%, about 400%, about 400%, about 500%, about 500%, about 600%, about 700%, about 800%, about 900%, about 1000%, about 1200%, about 1400%, about 1600%, about 1800%, about 1900%, about 2100%, about 2200%, about 2300%, about 2400%, about 2500%, about 2600%, about 2700%, about 2800%, about 3000%, about 3500%, about 4000%, about 4000%, about 5000%, about 5000%, about 6000%, about 7000%, about 8000%, about 9000%, about 10000%, about 12000%, about 14000%, about 15000%, about 16000%, about 18000%, about 25000%, about 26000%, about 27000%, about 28000%, about 30000%, about 35000%, about 40000%, about 40000%, about 5 %, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more decreased, or for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more decreased.
[0193] In one embodiment, the IL-2 fusion protein provided by the present disclosure comprises the property of altered (e.g., reduced or decreased) susceptibility to proteolysis in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has reduced or decreased susceptibility to proteolysis compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 fusion protein has reduced or decreased susceptibility to proteolysis compared to a reference IL-2 fusion protein. In one embodiment, the susceptibility of the IL-2 fusion protein to proteolysis is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the susceptibility of the IL-2 fusion protein to proteolysis is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0194] In one embodiment, the IL-2 fusion protein has an altered (e.g., enhanced or increased) resistance to proteolysis in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has an enhanced or increased resistance to proteolysis compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has an enhanced or increased resistance to proteolysis compared to a reference IL-2 fusion protein. In one embodiment, the resistance of the IL-2 fusion protein to proteolysis is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the resistance of the IL-2 fusion protein to proteolysis is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0195] In one embodiment, the IL-2 fusion protein has an altered (e.g., reduced or decreased) binding ability and / or binding affinity to human CD25 in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity to human CD25 compared to wild-type human IL-2. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity to human CD25 compared to a reference IL-2 fusion protein. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to human CD25 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein for human CD25 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding affinity for CD25 (e.g., human CD25) compared to, e.g., an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, e.g., by about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 5 ... A decrease of about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or a decrease of, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0196] In one embodiment, the IL-2 fusion protein has a potency of, e.g., about 5 to 500 pM, e.g., about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, about 1000, about 2000, about 3000, about 4000, about 5000, about 5000, about 6000, about 7000, about 8000, about 9000, about 10000, about 20000, about 30000, about 40000, about 50000, about 50000, about 60000, about 70000, about 80000, about 90000, about 10000, about 10000, about 20000, about 30000, about 40000, about 50000, about 50000, about 60000, about 60000, about 70000, about 80000, about 90000, about 10000, about 20000, about 30000, 00, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 200, 250, about 300, about 350, about 400, about 450, or about 500 pM, or, for example, about 10 to about 400 pM, about 20 to about 300 pM, about 50 to about 200 pM, about 100 to about 150 pM, about 5 to about 10 pM, for example, about 10 to about 20 pM, about 20 to about 30 pM, or about 30 to about 40 pM, For example, about 40 to about 50 pM, about 50 to about 60 pM, about 60 to about 70 pM, about 70 to about 80 pM, about 80 to about 90 pM, about 90 to about 100 pM, about 100 to about 110 pM, about 110 to about 120 pM, about 120 to about 130 pM, about 130 to about 140 pM, about 140 to about 150 pM, about 150 to about 200 pM, about 200 to about 250 pM, about 250 to about 300 pM, about 300 to about 350 pM, about 350 to about 400 pM, about 400 to about 500 pM, about 500 to about 600 pM, about 600 to about 700 pM, about 700 to about 800 pM, about 800 to about 900 pM, about 900 to about 100 pM, about 1000 to about 110 pM, about 1100 to about 120 pM, about 1200 to about 130 pM, about 130 A dissociation constant (K) of about 500 pM, or, for example, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 200, about 250, about 300, about 350, about 400, about 450, or greater than about 500 pM. D ) and binds to CD25 (e.g., human CD25) with low affinity.
[0197] In one embodiment, the IL-2 fusion protein has a cytoplasmic affinity of, for example, about 0.1 to 10 nM, e.g., about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 6, about 7, about 8, about 9, or about 10 nM, or for example, about 0.2 to about 5 nM, about 0.5 to about 2 nM, about 1 to 1.5 nM, about 0.1 to about 0.2 nM, e.g., about 0.2 to about 0.3 nM, about 0.3 to about 0. 4 nM, or about 0.4 to about 0.5 nM, for example, about 0.5 to about 0.6 nM, about 0.6 to about 0.7 nM, about 0.7 to about 0.8 nM, about 0.8 to about 0.9 nM, about 0.9 to about 1 nM, about 1 to about 1.5 nM, about 1.5 to about 2 nM, about 2.5 to about 3 nM, about 3.5 to about 4 nM, about 4 to about 4.5 nM, about 4.5 to about 5 nM , about 5 to about 6 nM, about 6 to about 7 nM, about 7 to about 8 nM, about 8 to about 9 nM, or about 9 to about 10 nM, or for example, about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 nM or more. D ) and binds to CD25 (e.g., human CD25) with low affinity.
[0198] In one embodiment, the IL-2 fusion protein has an altered (e.g., reduced or decreased) binding ability and / or binding affinity to human CD132 in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity to human CD132 compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity to human CD132 compared to a reference IL-2 fusion protein. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to human CD132 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to human CD132 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0199] In one embodiment, the IL-2 fusion protein has an altered (e.g., reduced or decreased) binding ability and / or binding affinity to a human dimeric IL-2 receptor comprising human CD122 and human CD132 in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity to a human dimeric IL-2 receptor comprising human CD122 and human CD132 compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity to a human dimeric IL-2 receptor comprising human CD122 and human CD132 compared to a reference IL-2 fusion protein. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to a human dimeric IL-2 receptor comprising human CD122 and human CD132 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to a human dimeric IL-2 receptor comprising human CD122 and human CD132 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0200] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced, increased, and / or selective) binding to Tregs in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased binding to Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has selective binding to Tregs compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 fusion protein has enhanced or increased binding to Tregs compared to a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has selective binding to Tregs compared to a reference IL-2 fusion protein. In one embodiment, the binding to Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, binding to Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0201] In one embodiment, the IL-2 fusion protein has a reduced or decreased binding affinity to a CD122 / CD132 heterodimer (e.g., a human CD122 / CD132 heterodimer), e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49 ... A decrease of about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or a decrease of, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0202] In one embodiment, the IL-2 fusion protein has a concentration of, e.g., about 0.2 to 20 nM, e.g., about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about 19 ... about 20 nM, or, for example, about 0.5 to about 15 nM, about 1 to about 10 nM, about 2 to about 5 nM, about 0.2 to about 0.3 nM, about 0.3 to about 0.4 nM, about 0.4 to about 0.5 nM, about 0.5 to about 0.6 nM, about 0.6 to about 0.7 nM, about 0.7 to about 0.8 nM, about 0.8 to about 0.9 nM, about 0.9 to about 1 nM, about 1 to about 1.1 nM, about 1.1 to about 1.2 nM, about 1.2 to about 1.3 nM, about 1.3 to about 1.4 nM, about 1.4 to about 1.5 nM, about 1.5 to about 2 nM, about 2 to about 3 nM, about 3 to about 4 nM, about 4 to about 5 nM, about 5 to about 6 nM, about 6 to about 7 nM, about 7 to about 8 nM, about 8 to about 9 nM, about 9 to about 10 nM, about 10 to about 11 nM, about 11 to about 12 nM, about 12 to about 13 nM, about 13 to about 14 nM, about 14 to about 15 nM, about 15 to about 16 nM, about 16 to about 17 nM, about 17 to about 18 nM, about 18 to about 19 nM, or about 19 to about 20 nM, or for example, about 0.2, about 0. about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about 20 nM.
[0203] In one embodiment, the IL-2 fusion protein has a cytoplasmic affinity of, for example, about 0.2 to 300 nM, e.g., about 0.2 nM, about 0.5 nM, about 1 nM, about 2 nM, about 5 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 110 nM, about 120 nM, about 130 nM, about 140 nM, about 150 nM, about 160 nM, about 170 nM, about 180 nM, about 190 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 260 nM, about 270 nM, about 280 nM, about 290 nM, about 300 nM, about 310 nM, about 320 nM, about 330 nM, about 340 nM, about 350 nM, about 360 nM, about 370 nM, about 380 nM, about 390 nM, about 40 ...500 nM, about 500 nM, about 600 nM, about 700 nM, about 800 nM, about 900 nM, about 1000 nM, about 11 about 120 nM, about 130 nM, about 140 nM, about 150 nM, about 160 nM, about 170 nM, about 180 nM, about 190 nM, about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 260 nM, about 270 nM, about 280 nM, about 290 nM, or about 300 nM, or for example, about 0.5 to about 15 nM, about 1 to about 10 nM, about 2 to about 5 nM, about 0.2 nM to about 0.5 nM, about 0.5 nM to about 1 nM, about 1 to about 2 nM, about 2 nM to about 5 nM, about 5 nM to about 10nM, about 10nM to about 15nM, about 15nM to about 20nM, about 20nM to about 25nM, about 25 to about 30nM, about 30nM to about 40nM, about 40nM to about 50nM, about 50 to about 60nM, about 60 to about 70nM, about 70nM to about 80 nM, approximately 80nM to approximately 90nM, approximately 90nM to approximately 100nM, approximately 100nM to approximately 110nM, approximately 110nM to approximately 120nM, approximately 120nM to approximately 130nM, approximately 130nM to approximately 140nM, approximately 140nM to approximately 150nM, approximately 150nM to approximately 160 nM, about 160 nM to about 170 nM, about 170 nM to about 180 nM, about 180 nM to about 190 nM, about 190 nM to about 200 nM, about 200 nM to about 210 nM, about 210 nM to about 220 nM, about 220 nM to about 230 nM, about 230 nM to about 240 nM, about 240 nM to about 250 nM, about 250 nM to about 260 nM, about 260 nM to about 270 nM, about 270 nM to about 280 nM, about 280 nM to about 290 nM, or about 290 nM to about 300 nM, or for example, greater than about 0.2, about 0.5, about 1, about 2, about 5, about 10, about 15, about 20nM, about 25nM, about 30nM, about 40nM, about 50nM, about 60nM, about 70nM, about 80nM, about 90n M, about 100nM, about 110nM, about 120nM, about 130nM, about 140nM, about 150nM, about 160nM, about 170nM, about 180nM, about 190nM, It binds to low affinity CD122 / CD132 heterodimers (e.g., human CD122 / CD132 heterodimers) with a dissociation constant (KD) of greater than about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 260 nM, about 270 nM, about 280 nM, about 290 nM, or about 300 nM.
[0204] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced, increased, and / or selective) binding to Tregs in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased binding to Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has selective binding to Tregs compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 fusion protein has enhanced or increased binding to Tregs compared to a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has selective binding to Tregs compared to a reference IL-2 fusion protein. In one embodiment, the binding to Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, binding to Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0205] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced, increased, and / or selective) activation of the IL-2 signaling pathway in Tregs in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased activation of the IL-2 signaling pathway in Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has selective activation of the IL-2 signaling pathway in Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has enhanced or increased activation of the IL-2 signaling pathway in Tregs compared to a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has selective activation of the IL-2 signaling pathway in Tregs compared to a reference IL-2 fusion protein. In one embodiment, activation of the IL-2 signaling pathway in Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, activation of the IL-2 signaling pathway in Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0206] In one embodiment, the IL-2 fusion protein has a IL-2 fusion protein activity that is, for example, about 1, about 2, about 3, about 4, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58 Selectively activates IL-2 signaling in T regulatory cells in vitro and / or in vivo having a T helper EC50 / Treg EC50 ratio of greater than 4, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, or about 3000 or more.
[0207] In one embodiment, the IL-2 fusion protein has a IL-2 fusion protein activity greater than or equal to about 1, about 2, about 3, about 4, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 20 00, 2500, or greater than about 3000 or more, or for example, 1 and greater than about 1-2, about 2-3, about 3-4, about 4-5, 1 to greater than about 1-10, 1 and greater than about 1-20, 1 to greater than about 1-30, 1 and greater than about 1-40, 1 and greater than about 1-50, about 2-10, about 2-20, about 2-30, about 2-40, 2-50, about 5-10, about Selectively activates IL-2 signaling in T regulatory cells in vitro and / or in vivo having an NK cell EC50 / Treg EC50 ratio of 5-20, about 5-30, about 5-40, about 5-50, about 10-20, about 10-30, about 10-40, about 10-50, about 20-40, about 20-50, about 50-100, about 100-200, about 200-500, about 500-1000, about 1000-2000, or about 1000-3000.
[0208] In one embodiment, the IL-2 fusion protein has an altered (e.g., enhanced, increased, and / or selective) ability to induce or promote expansion, activity, survival, and / or proliferation of Tregs in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has an enhanced or increased ability to induce or promote expansion, activity, survival, and / or proliferation of Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has a selective ability to induce or promote expansion, activity, survival, and / or proliferation of Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has an enhanced or increased ability to induce or promote expansion, activity, survival, and / or proliferation of Tregs compared to a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has a selective ability to induce or promote Treg expansion, activity, survival and / or proliferation compared to a reference IL-2 fusion protein. In one embodiment, the ability to induce or promote Treg expansion, activity, survival and / or proliferation is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the ability to induce or promote Treg expansion, activity, survival and / or proliferation is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.
[0209] In one embodiment, the IL-2 fusion protein has enhanced or increased potency and / or ability to induce or promote T regulatory cell activity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 105%, about 100%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, about 120%, about 122%, about 123%, about 124%, about 125%, about 126%, about 127%, about 128%, about 129%, about 130%, about 131%, about 132%, about 133%, about 134%, about 135%, about 136%, about 137%, about 138%, about 140%, about 142%, about 144%, about 145%, about 146%, about 147%, about 148%, about 149%, about 150%, about 151%, about 152%, about 153%, about 154%, about 155%, about 156%, about 157%, about 158%, about 159%, about 160%, about 161%, about 162%, about 163%, about 164%, about 165%, about 166 or has an EC50 against Treg that is reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.
[0210] In one embodiment, the IL-2 fusion protein has a reduced or diminished potency and / or ability to induce or promote T regulatory cell activity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95 ... 0%, about 85%, about 90%, about 95%, about 100% or more higher, or reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold, about 50-fold, about 100-fold, about 200-fold, about 500-fold, about 1000-fold, about 2000-fold, about 5000-fold, about 10,000-fold, about 15,000-fold, about 20,000-fold or more.
[0211] In one embodiment, the T helper cells described herein are CD45+CD3+CD4+Foxp3- cells, e.g., as determined by flow cytometry. In one embodiment, the Tregs described herein are CD45+CD3+CD4+Foxp3+ cells, e.g., as determined by flow cytometry. In one embodiment, the NK cells described herein are CD45+CD3- cells that are CD56+ and / or CD16+, e.g., as determined by flow cytometry. In one embodiment, the NK cells described herein are CD45+CD3-CD56+ cells, e.g., as determined by flow cytometry.
[0212] In one embodiment, the IL-2 fusion protein has one or more structural and / or functional properties that are the same or substantially the same as an IL-2 fusion protein that comprises wild-type IL-2 or a reference IL-2 fusion protein.
[0213] In one embodiment, the reference IL-2 fusion protein comprises an amino acid sequence having about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an IL-2 fusion protein described herein. In one embodiment, the reference IL-2 fusion protein comprises an IL-2 variant comprising the amino acid sequence of SEQ ID NO: 57. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO: 57 and includes one or more (2, 3, 4, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions) described herein.
[0214] In one embodiment, the IL-2 fusion protein comprises an IL-2 polypeptide (e.g., a human IL-2 polypeptide) described herein. In one embodiment, the IL-2 fusion protein is encoded by a nucleic acid comprising a nucleotide sequence described herein.
[0215] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all) of the positions in IL-2 described herein. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all) of the positions in IL-2 selected from T3, H16, I28, K35, R38, F42, E68, V69, Q74, D84, S87, N88, I92, C125, or Q126.
[0216] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position T3 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position H16 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position I28 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position K35 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position R38 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position F42 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position E68 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position V69 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position Q74 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position D84 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position S87 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position N88 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position I92 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position C125 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position Q126 in IL-2.
[0217] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at positions V69, Q74, or both in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at positions V69 and Q74 in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution V69A in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q74P in IL-2.
[0218] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position H16, I92, D84, or a combination thereof in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position H16, optionally the amino acid substitution is H16N, H16L, or H16D in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution H16N in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution H16L in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution H16D in IL-2.
[0219] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position 192, optionally the amino acid substitution is 192S in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution 192S in IL-2.
[0220] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position D84, optionally the amino acid substitution is D84V in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution D84V in IL-2.
[0221] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position K35, R38, F42, E68, or a combination thereof in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position K35, optionally the amino acid substitution is K35E in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution K35E in IL-2.
[0222] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position R38, optionally the amino acid substitution is R38E, R38N or R38Q in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution R38N in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution R38Q in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position F42, optionally the amino acid substitution is F42K or F42Q in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution F42K in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution F42Q in IL-2.
[0223] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at one, two, or all of the following in IL-2: (i) (a) positions V69 and Q74, (b) K35, or (c) positions V69, Q74, and K35, and (ii) positions H16, I92, or D84. In one embodiment, the IL-2 fusion protein further comprises an amino acid modification (e.g., substitution) at one, two, or all of the following positions in IL-2: R38, F42, or E68.
[0224] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) in IL-2 at: (i)(a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74 and K35, and (ii)(a) one, two, or all of positions H16, I92 or D84, or (b) one, two, or all of positions R38, F42 or E68.
[0225] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) in IL-2 at: (i)(a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74 and K35, and (ii)(a) one, two, or all of positions H16, I92 or D84, and (b) one, two, or all of positions R38, F42 or E68.
[0226] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, and H16, optionally the amino acid substitutions are V69A, Q74P, and H16N or H16L, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and H16N or H16L in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and H16N in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and H16N in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and H16L in IL-2.
[0227] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, and I92, optionally the amino acid substitutions are V69A, Q74P, and I92S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and I92S in IL-2.
[0228] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, and D84, optionally the amino acid substitutions are V69A, Q74P, and D84V, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and D84V in IL-2.
[0229] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and R38, optionally the amino acid substitutions are V69A, Q74P and R38Q, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P and R38Q in IL-2.
[0230] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and F42, optionally the amino acid substitutions are V69A, Q74P and F42Q, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P and F42Q in IL-2.
[0231] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and R38, optionally the amino acid substitutions are V69A, Q74P and R38N, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P and R38N in IL-2.
[0232] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74 and R38, optionally the amino acid substitutions are V69A, Q74P and R38E, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P and R38E in IL-2.
[0233] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, K35 and H16, optionally the amino acid substitutions are V69A, Q74P, K35E and H16N, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, K35E and H16N in IL-2.
[0234] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, K35, H16 and R38, optionally the amino acid substitutions are V69A, Q74P, K35E, H16N and R38N, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, K35E, H16N and R38N in IL-2.
[0235] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, H16 and R38, optionally the amino acid substitutions are V69A, Q74P, H16N and R38N or R38Q, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, H16N and R38N or R38Q in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, H16N and R38N in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, H16N and R38N in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, H16N and R38Q in IL-2.
[0236] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (eg, a substitution) at position I28, E68, S87, N88, Q126, or a combination thereof in IL-2.
[0237] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position I28, optionally the amino acid substitution is I28T or I28F in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution I28T in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution I28F in IL-2.
[0238] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position E68, optionally the amino acid substitution is E68Q or E68N in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution E68Q in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution E68N in IL-2.
[0239] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position S87, optionally the amino acid substitution is S87R in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution S87R in IL-2.
[0240] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position N88, optionally the amino acid substitution is N88S, N88L, or N88D in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution N88S, N88L, or N88D in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution N88S in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution N88L in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution N88D in IL-2.
[0241] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position Q126, optionally the amino acid substitution is Q126T, Q126K or Q126R in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126T, Q126K or Q126R in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126T, Q126K or Q126R in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126T in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126K in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126R in IL-2.
[0242] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position C125 in IL-2, optionally the amino acid substitution is C125S. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution C125S in IL-2.
[0243] In one embodiment, the IL-2 fusion protein comprises an amino acid modification (e.g., substitution) at position T3 in IL-2, optionally the amino acid substitution is T3A. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution T3A in IL-2.
[0244] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions V69, Q74, and C125 in IL-2, optionally the amino acid substitutions are V69A, Q74P, and C125S, respectively. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and C125S in IL-2.
[0245] In one embodiment, the IL-2 fusion protein includes an amino acid modification (e.g., substitution) at positions T3, H16, I92, or a combination thereof in IL-2, optionally, the amino acid substitutions are T3A, H16N, and I92S, respectively, in IL-2.
[0246] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions H16, V69, Q74 and C125 in IL-2, optionally the amino acid substitutions are H16N, V69A, Q74P and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16N, V69A, Q74P and C125S in IL-2.
[0247] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions H16, V69, Q74 and C125 in IL-2, optionally the amino acid substitutions are H16L, V69A, Q74P and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16L, V69A, Q74P and C125S in IL-2.
[0248] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions H16, V69, Q74, I92 and C125 in IL-2, optionally the amino acid substitutions are H16L, V69A, Q74P, I92S and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16L, V69A, Q74P, I92S and C125S in IL-2.
[0249] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions T3, V69, Q74 and C125 in IL-2, optionally the amino acid substitutions are T3A, V69A, Q74P and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, V69A, Q74P and C125S in IL-2.
[0250] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions T3, H16, V69, Q74 and C125 in IL-2, optionally the amino acid substitutions are T3A, H16N or H16L, V69A, Q74P and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, H16N, V69A, Q74P and C125S. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, H16L, V69A, Q74P and C125S in IL-2.
[0251] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions T3, V69, Q74, I92 and C125 in IL-2, optionally the amino acid substitutions are T3A, V69A, Q74P, I92S and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, V69A, Q74P, I92S and C125S in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, V69A, Q74P, I92S and C125S in IL-2.
[0252] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions H16, K35, V69 and Q74, optionally the amino acid substitutions are H16L, K35E, V69A and Q74P, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16L, K35E, V69A and Q74P in IL-2.
[0253] In one embodiment, the IL-2 fusion protein comprises amino acid modifications (e.g., substitutions) at positions H16, R38, V69A and Q74P, optionally the amino acid substitutions are H16L, R38Q, V69A and Q74P, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16L, R38Q, V69A and Q74P in IL-2.
[0254] In one embodiment, the IL-2 fusion protein contains the amino acid substitutions H16L, V69A, Q74P and C125S in IL-2.
[0255] Without wishing to be bound by theory, in one embodiment, an IL-2 fusion protein comprising the amino acid substitutions H16L, V69A, Q74P and C125S may have at least one or more of the following advantageous properties: (i) have reduced binding affinity to CD122 and / or CD132, which increases the potency and selectivity of the IL-2 agent for regulatory T cells (Tregs) compared to other T cell types; (ii) are significantly more stable, e.g., due to the presence of the stabilizing mutations V69A and Q74P; (iii) have reduced or decreased binding capacity and / or binding affinity to CD25, which improves the longevity of the IL-2 agent; (iv) do not substantially promote the expansion, activity, survival and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo; and / or (v) have reduced imprecise disulfide pairing and improved stability, e.g., due to the presence of the C125S mutation. In one embodiment, IL-2 agents containing the H16L mutation have reduced binding affinity for CD122 and / or CD132, and / or increased potency and selectivity for Tregs over other T cell types, compared to IL-2 agents containing other H16 mutations. These properties make IL-2 variants containing the amino acid substitutions H16L, V69A, Q74P and C125S particularly suitable for treating disorders and conditions resulting from aberrant immune responses.
[0256] Thus, in one embodiment, an IL-2 fusion protein comprising the amino acid substitutions H16L, V69A, Q74P and C125S has one or more (e.g., 2, 3, 4, 5, 6, 7, or all) of the following properties relative to wild-type IL-2 or a reference IL-2 variant that does not comprise the amino acid substitutions: (i) enhanced or increased stability in vitro or in vivo, (ii) reduced or decreased binding ability and / or binding affinity to human CD122 in vitro and / or in vivo, (iii) reduced or decreased binding ability and / or binding affinity to human CD122 in vitro and / or in vivo, (iv) reduced or increased binding ability and / or affinity to human CD122 in vivo and / or (v) reduced or increased binding ability and / or affinity to human CD122 in vivo and / or (vi) reduced or increased binding ability and / or affinity to human CD122 in vivo and / or (vii ... (iv) reduced or decreased affinity of the IL-2 variant for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) reduced or decreased or substantially unchanged binding ability and / or binding affinity for human CD25 in vitro and / or in vivo; (vi) reduced or decreased binding ability and / or binding affinity for regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in T regulatory cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote Treg expansion, activity, survival and / or proliferation.
[0257] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO and IL-2 variants comprising an amino acid sequence selected from SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:1000, SEQ ID NO:1001, SEQ ID NO:1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0258] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant comprising an amino acid sequence of SEQ ID NO:4, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises an IL-2 variant comprising an amino acid sequence of SEQ ID NO:5, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence of SEQ ID NO:11, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence of SEQ ID NO: 1000, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.In one embodiment, the IL-2 fusion protein comprises an amino acid sequence of SEQ ID NO: 1001, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence of SEQ ID NO: 1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0259] In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 4 or 5, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 4, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 5, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 11, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1000, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1001, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1002, or a functional fragment thereof.
[0260] Without wishing to be bound by theory, in one embodiment, an IL-2 fusion protein comprising the amino acid sequence of SEQ ID NO:5 or a functional fragment thereof can have at least one or more of the following advantageous properties: (i) has reduced binding affinity to CD122 and / or CD132, which increases the potency and selectivity of the IL-2 agent for regulatory T cells (Tregs) compared to other T cell types; (ii) is significantly more stable, e.g., due to the presence of stabilizing mutations V69A and Q74P; (iii) has reduced or decreased binding ability and / or binding affinity to CD25, which improves the longevity of the IL-2 agent; (iv) does not substantially promote the expansion, activity, survival and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo; and / or (v) has reduced imprecise disulfide pairing and improved stability, e.g., due to the presence of a C125S mutation. In one embodiment, IL-2 agents containing the H16L mutation have reduced binding affinity for CD122 and / or CD132, and / or increased potency and selectivity for Tregs over other T cell types, compared to IL-2 agents containing other H16 mutations. These properties make IL-2 fusion proteins containing the amino acid sequence of SEQ ID NO:5 particularly suitable for treating disorders and conditions resulting from an aberrant immune response.
[0261] Thus, in one embodiment, an IL-2 fusion protein comprising an amino acid sequence of SEQ ID NO:5, or a functional fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids, has, inter alia, one or more (e.g., 2, 3, 4, 5, 6, 7, or all) of the following properties relative to wild-type IL-2 or a reference IL-2 fusion protein that does not contain amino acid substitutions: (i) enhanced or increased stability in vitro or in vivo. (ii) a reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iii) a reduced or decreased binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; (iv) a reduced or decreased affinity of the IL-2 fusion protein for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) a reduced or decreased or substantially unchanged binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; (vi) a reduced or decreased binding capacity and / or binding affinity to regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in T regulatory cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote Treg expansion, activity, survival and / or proliferation.
[0262] In one embodiment, an IL-2 fusion protein described herein comprises an Fc region, e.g., an Fc region having one or more mutations described herein and / or having one or more structural or functional properties described herein. Without wishing to be bound by theory, it is believed that in one embodiment, the Fc region described herein can reduce (e.g., prevent) renal clearance and / or extend the half-life of the IL-2 agent (e.g., via FcRn).
[0263] As used herein, the term "fusion protein" refers to a protein that includes two or more protein or peptide components. The two or more protein or peptide components may be obtained from different sources or may be encoded by different genes. A fusion protein may also be referred to as a chimeric protein. An Fc fusion protein (also known as an Fc chimeric fusion protein, Fc-Ig, Ig-based chimeric fusion protein, or Fc tag protein) may include an Fc region of an immunoglobulin (e.g., an Fc region described herein) linked (e.g., fused) to a protein or peptide. The Fc region can be linked (e.g., genetically fused) to the protein or peptide directly or indirectly, e.g., via a linker. In one embodiment, the Fc region is derived from an Fc region of an IgG, such as, for example, human IgG, e.g., IgG1, IgG2, IgG3, or IgG4. In one embodiment, the Fc region is derived from an IgG1 Fc region, e.g., human IgG1.
[0264] An IL-2 fusion protein may comprise an IL-2 variant (e.g., an IL-2 variant described herein) or a functional fragment thereof linked (e.g., fused) to a protein or peptide. In one embodiment, the IL-2 fusion protein is an IL-2-Fc fusion protein, e.g., further comprising an Fc region of an immunoglobulin (e.g., an Fc region described herein) linked (e.g., fused) to an IL-2 polypeptide (e.g., an IL-2 variant described herein) or a functional fragment thereof. In one embodiment, the IL-2 fusion protein is not an IL-2-Fc fusion protein, e.g., an IL-2 fusion variant described herein or a functional fragment thereof, but is linked (e.g., fused) to a protein or peptide other than the Fc region of an IgG, e.g., human IgG, e.g., IgG1, IgG2, IgG3, or IgG4.
[0265] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, The present invention includes an amino acid sequence selected from SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0266] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, The present invention includes an amino acid sequence selected from SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, or SEQ ID NO:131, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0267] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160. , SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, or SEQ ID NO:169, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0268] In one embodiment, the IL-2 fusion protein is SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198 , SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, or SEQ ID NO:207, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0269] In one embodiment, the IL-2 fusion protein is SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236 , SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, or SEQ ID NO:245, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0270] In one embodiment, the IL-2 fusion protein is SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:269, SEQ ID NO:270, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274 , SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, or SEQ ID NO:283, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0271] In one embodiment, the IL-2 fusion protein is SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312 , SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, or SEQ ID NO:321, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0272] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:350. , SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, or SEQ ID NO:359, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0273] In one embodiment, the IL-2 fusion protein comprises an amino acid sequence selected from: 1004, SEQ ID NO:1005, SEQ ID NO:1006, SEQ ID NO:1007, SEQ ID NO:1008, SEQ ID NO:1009, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1004, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1005, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence of SEQ ID NO: 1006, an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1007, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence of SEQ ID NO: 1008, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0274] In one embodiment, the IL-2 agent comprises the amino acid sequence of any of SEQ ID NOs: 1004-1009, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1007 or 1008, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1004, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1005, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1006, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1007, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1008, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1009, or a functional fragment thereof.
[0275] Without wishing to be bound by theory, in one embodiment, an IL-2 fusion protein comprising the amino acid sequence of SEQ ID NO: 1008 or a functional fragment thereof may also have at least one or more of the following advantageous properties: (i) it has a reduced binding affinity to CD122 and / or CD132, which increases the potency and selectivity of IL-2 agents for regulatory T cells (Tregs) compared to other T cell types; (ii) it is significantly more stable, e.g., due to the presence of stabilizing mutations V69A and Q74P; (iii) it has a reduced or no binding affinity to CD25; (iv) does not substantially promote the expansion, activity, survival and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo, and / or (v) has reduced imprecise disulfide pairing and improved stability, e.g., due to the presence of the C125S mutation, and / or (vi) has reduced effector function, e.g., due to Fc glycosylation, e.g., due to the N297G mutation in the Fc region. In one embodiment, the IL-2 agent comprising the H16L mutation has reduced binding affinity to CD122 and / or CD132, and / or increased potency and selectivity for Treg over other T cell types, compared to IL-2 agents comprising other H16 mutations. These properties make the IL-2 fusion protein comprising the amino acid sequence of SEQ ID NO: 1008 particularly suitable for treating disorders and conditions resulting from abnormal immune responses.
[0276] Thus, in one embodiment, an IL-2 fusion protein comprising an amino acid sequence of SEQ ID NO: 1008, or a functional fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30, 35, 40, 45, or 50 amino acids, in particular has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, or all) of the following properties relative to wild-type IL-2 or a reference IL-2 fusion protein that does not contain amino acid substitutions: (i) Ability to selectively bind to a wild-type IL-2 or a reference IL-2 fusion protein that does not contain amino acid substitutions in vitro or in vivo. (ii) a reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iii) a reduced or decreased binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; (iv) a reduced or decreased affinity of the IL-2 fusion protein for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., a human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) a reduced or decreased or substantially unchanged binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; (vi) a reduced or decreased or substantially unchanged binding capacity and / or binding affinity to regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in T regulatory cells (Tregs) in vitro or in vivo; (viii) enhanced or increased ability to induce or promote Treg expansion, activity, survival and / or proliferation; or (ix) reduced or decreased effector function.
[0277] In one embodiment, the IL-2 fusion protein comprises, from N-terminus to C-terminus, an IL-2 variant described herein and an Fc region (e.g., an Fc region described herein). In one embodiment, the fusion protein further comprises a linker (e.g., a linker described herein) between the IL-2 variant and the Fc region. In one embodiment, the IL-2 fusion forms a dimer, e.g., a homodimer.
[0278] In one embodiment, the fusion protein contains one or more glycosylation sites or is glycosylated, hi another embodiment, the fusion protein does not have a glycosylation site or is unglycosylated.
[0279] In one embodiment, the only amino acids in the fusion protein are standard amino acids. In one embodiment, the fusion protein comprises naturally occurring amino acids, their analogs, derivatives, and congeners, amino acid analogs with variant side chains, and / or any stereoisomers of any of the foregoing. The fusion protein may comprise the D-optical isomer or the L-optical isomer of amino acids and peptidomimetics.
[0280] In one aspect, the disclosure provides a method of making the IL-2 fusion protein disclosed herein. The IL-2 fusion protein described herein can be produced by any suitable recombinant DNA technology. In one embodiment, the method comprises culturing a cell containing a nucleic acid encoding the IL-2 fusion protein under conditions that allow for the production of the fusion protein. In another embodiment, the method further comprises isolating or purifying the IL-2 fusion protein. In yet another embodiment, the method further comprises evaluating the efficacy of the IL-2 fusion protein in a cell-based assay or an animal model. In yet another embodiment, the method further comprises administering the IL-2 fusion protein to a subject, e.g., a human.
[0281] The present disclosure provides isolated nucleic acid molecules encoding the IL-2 fusion proteins described herein, as well as vectors and host cells thereof. Nucleic acid molecules include, but are not limited to, RNA, genomic DNA, and cDNA.
[0282] IL-2 complex In one embodiment, the IL-2 agent comprises an IL-2 conjugate, such as an IL-2 conjugate described herein. In one embodiment, the IL-2 conjugate is an IL-2 / anti-IL-2 antibody immune complex (IL-2 ic).
[0283] Without wishing to be bound by theory, in one embodiment, it is believed that IL-2 complexes, such as IL-2 / anti-IL-2 antibody immune complexes, can enhance the biological activity of IL-2 in vivo. For example, the effect of IL-2 on cells (e.g., Tregs) can be modulated by complexing IL-2 with a separate mAb that specifically binds IL-2. The mechanism can include, for example, extending the cytokine half-life in circulation. Depending on the clone of the IL-2 antibody, IL-2 ic can selectively stimulate, for example, CD25high cells (e.g., IL-2 / JES6-1 immune complexes), or CD122high cells (e.g., IL-2 / S4B6 immune complexes). For example, IL-2 / JES6-1 immune complexes highly selectively stimulate regulatory T cells and can be useful in the treatment of transplantation and autoimmune diseases. As another example, IL-2 / S4B6 immune complexes can have high stimulatory activity for NK cells and memory CD8+ T cells, and can replace conventional IL-2 in cancer immunotherapy.
[0284] In one embodiment, the IL-2 complex comprises an IL-2 variant as described herein. In one embodiment, the IL-2 complex comprises one or more amino acid modifications (e.g., substitutions) as described in Table 9. In one embodiment, the IL-2 complex comprises an amino acid sequence as described in Table 9, or a functional fragment thereof. In one embodiment, the IL-2 complex comprises an anti-IL-2 antibody molecule. In one embodiment, the IL-2 complex comprises an IL-2 variant and an anti-IL-2 antibody molecule as described herein. In one embodiment, the anti-IL-2 antibody molecule binds to the IL-2 variant. In one embodiment, the anti-IL-2 antibody molecule is capable of binding to the IL-2 variant and wild-type IL-2. In one embodiment, the IL-2 variant comprises one or more mutations as described herein. In one embodiment, the one or more mutations do not reduce or do not substantially reduce binding of the IL-2 variant to the anti-IL-2 antibody molecule.
[0285] In one embodiment, the IL-2 complex is SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO 4. An amino acid sequence selected from SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:1000, SEQ ID NO:1001, SEQ ID NO:1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0286] In one embodiment, the IL-2 complex modulates (e.g., stimulates) one or more activities of T cells. In one embodiment, the IL-2 complex stimulates CD25high cells. In one embodiment, the IL-2 complex stimulates Tregs. In one embodiment, the IL-2 complex stimulates CD122high cells. In one embodiment, the IL-2 complex stimulates NK cells and / or memory CD8+ T cells. In one embodiment, the IL-2 complex selectively stimulates CD25high cells over CD122high cells. In one embodiment, the IL-2 complex selectively stimulates CD122high cells over CD25high cells. In one embodiment, the IL-2 complex selectively stimulates Tregs over NK cells and / or memory CD8+ T cells. In one embodiment, the IL-2 complex selectively stimulates NK cells and / or memory CD8+ T cells over Tregs.
[0287] Exemplary anti-IL-2 antibody molecules suitable for use are described, for example, in International Application Publication No. WO2016 / 164937, which is incorporated herein by reference in its entirety.
[0288] As used herein, the term "antibody molecule" refers to a protein that contains at least one immunoglobulin variable domain sequence, e.g., an immunoglobulin chain or fragment thereof. The term "antibody molecule" includes, for example, full-length, mature antibodies, and antigen-binding fragments of antibodies. For example, an antibody molecule may contain a heavy (H) chain variable domain sequence (abbreviated herein as VH), and a light (L) chain variable domain sequence (abbreviated herein as VL). In another example, an antibody molecule contains two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequences, thereby forming two antigen-binding sites, e.g., Fab, Fab', F(ab')2, Fc, Fd, Fd', Fv, single-chain antibodies (e.g., scFv), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which may be generated by modification of whole antibodies or de novo synthesis using recombinant DNA technology. These functional antibody fragments retain the ability to selectively bind to their respective antigens or receptors. The antibodies and antibody fragments may be from any class of antibody, including but not limited to IgG, IgA, IgM, IgD, and IgE, and from any subclass of antibody (e.g., IgG1, IgG2, IgG3, and IgG4). The antibody molecules may be monoclonal or polyclonal. The antibody molecules may also be human, humanized, CDR-grafted, or in vitro generated antibodies. The antibody molecules may have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, or IgG4. The antibody molecules may also have a light chain selected from, for example, kappa or lambda. The term "immunoglobulin" (Ig) is used interchangeably with the term "antibody" herein.
[0289] Examples of antigen-binding fragments include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) an F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a diabody (dAb) fragment consisting of the VH domain; (vi) a camelid or camelized variable domain; (vii) a single chain Fv (scFv), see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; and (viii) a single domain antibody. These antibody fragments may be obtained using any suitable method, including a number of conventional techniques known to those with skill in the art, and the fragments may be screened for utility in the same manner as are intact antibodies.
[0290] The term "antibody" includes intact molecules as well as functional fragments thereof. The constant region of an antibody can be altered (e.g., mutated) to modify the properties of the antibody (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function).
[0291] The antibody molecule may be a single chain antibody. Single chain antibodies (scFV) may be engineered (see, for example, Colcher, D. et al. (1999) Ann NY Acad Sci 880:263-80, and Reiter, Y. (1996) Clin Cancer Res 2:245-52). Single chain antibodies can be dimerized or multimerized to generate multivalent antibodies with specificity for different epitopes of the same target protein.
[0292] The antibody molecule disclosed herein may also be a single domain antibody. A single domain antibody may include an antibody whose complementarity determining region is part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally lacking light chains, single domain antibodies derived from conventional four-chain antibodies, engineered antibodies, and single domain scaffolds other than those derived from antibodies. A single domain antibody may be any of the art or any future single domain antibody. A single domain antibody may be derived from any species, including, but not limited to, mouse, human, camel, llama, fish, shark, goat, rabbit, and cow. According to some embodiments, a single domain antibody is a naturally occurring single domain antibody known as a heavy chain antibody lacking light chains. Such single domain antibodies are disclosed, for example, in WO94 / 04678. For clarity, this variable domain derived from a heavy chain antibody naturally lacking light chains is known herein as a VHH or nanobody, to distinguish it from the conventional VH of four-chain immunoglobulins. Such VHH molecules may be derived from antibodies produced in Camelidae species, such as camel, llama, dromedary, alpaca, and guanaco. Other non-Camelidae species may produce heavy chain antibodies naturally devoid of light chains, and such VHHs are also contemplated.
[0293] The VH and VL regions can be subdivided into regions of hypervariability called "complementarity determining regions" (CDRs), interspersed with more conserved regions called "framework regions" (FR or FW). As used herein, the terms "complementarity determining regions" and "CDRs" refer to sequences of amino acids in antibody variable regions that confer antigen specificity and binding affinity. As used herein, the terms "framework", "FW", and "FR" are used interchangeably.
[0294] The extent of framework regions and CDRs have been precisely defined by a number of methods (see Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917; and the AbM definition used by Oxford Molecular's AbM antibody modeling software. See generally, e.g., Protein Sequence and Structure Analysis of Antibody Variable Domains in the Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). In one embodiment, the following definitions are used: the AbM definition of CDR1 of the heavy chain variable domain and the Kabat definitions of the other CDRs. In one embodiment, the Kabat definitions are used for all CDRs. Furthermore, the Kabat or AbM The embodiments described with respect to CDRs may also be implemented using Chothia hypervariable loops. Each VH and VL typically comprises three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
[0295] As used herein, "immunoglobulin variable domain sequence" refers to an amino acid sequence capable of forming the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally occurring variable domain. For example, the sequence may or may not include one, two or more N-terminal or C-terminal amino acids, or may include other modifications that are compatible with the formation of a protein structure.
[0296] The term "antigen-binding region" refers to the portion of an antibody molecule that contains the determinants that form the antigen-binding interface, or epitope thereof. For proteins (or protein mimetics), the antigen-binding region typically includes one or more loops (e.g., at least four amino acid or amino acid mimetic loops) that form the antigen-binding interface. Typically, the antigen-binding region of an antibody molecule includes at least one or two CDRs and / or hypervariable loops, or more typically at least three, four, five or six CDRs and / or hypervariable loops.
[0297] In this specification, the term "competition" or "cross-competition" is used interchangeably to refer to the ability of an antibody molecule to prevent another antibody molecule from binding to a target. The interference with binding can be direct or indirect (e.g., through allosteric regulation of the antibody molecule or the target). The degree to which an antibody molecule can interfere with the binding of another antibody molecule to a target, and therefore can be said to compete, can be determined using a competitive binding assay, such as a FACS assay, an ELISA assay, or a BIACORE assay. In one embodiment, the competitive binding assay is a quantitative competitive assay. In one embodiment, a first antibody molecule is said to compete for binding to a target with a second antibody molecule when binding of the first antibody molecule to the target is reduced by 10% or more, e.g., 20% or more, 30% or more, 40% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, or more, in a competitive binding assay (e.g., a competitive assay described herein).
[0298] As used herein, the term "monoclonal antibody" or "monoclonal antibody composition" refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. Monoclonal antibodies can be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods).
[0299] A "effectively human" protein is one that does not induce a neutralizing antibody response, such as a human anti-mouse antibody (HAMA) response. HAMA can be problematic in many situations, for example, when antibody molecules are administered repeatedly, for example, in the treatment of chronic or recurrent disease states. HAMA responses can potentially render repeated antibody administration ineffective, due to increased antibody clearance from serum (see, for example, Saleh et al., Cancer Immunol. Immunother. 32:180-190 (1990)) and due to potential allergic reactions (see, for example, LoBuglio et al., Hybridoma, 5:5117-5123 (1986)).
[0300] The antibody molecule may be a polyclonal or monoclonal antibody. In one embodiment, the antibody may be recombinantly produced, e.g., produced by any suitable phage display or combinatorial method.
[0301] Various phage display and combinatorial methods for generating antibodies are known in the art (see, e.g., Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. International Publication No. WO 92 / 18619; Dower et al. International Publication No. WO 91 / 17271; Winter et al. International Publication No. WO 92 / 20791; Markland et al. International Publication No. WO 92 / 15679; Breitling et al. International Publication No. WO 93 / 01288; McCafferty et al. International Publication No. WO 92 / 01047; Garrard et al. International Publication No. WO 92 / 09690; Ladner et al. International Publication No. WO 90 / 02809; Fuchs et al. (1991) Bio / Technology 9:1370-1372, Hay et al. (1992) Hum Antibod Hybridomas 3:81-85, Huse et al. (1989) Science 246:1275-1281, Griffiths et al. (1993) EMBO J 12:725-734, Hawkins et al. (1992) J Mol Biol 226:889-896, Clackson et al. (1991) Nature 352:624-628, Gram et al. (1992) PNAS 89:3576-3580, Garrad et al. (1991) Bio / Technology 9:1373-1377, Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137, and Barbas et al. al. (1991) PNAS 88:7978-7982, the entire contents of which are incorporated herein by reference).
[0302] In one embodiment, the antibody molecule is a fully human antibody (e.g., an antibody made in a mouse genetically engineered to produce antibodies from human immunoglobulin sequences), or a non-human antibody, e.g., a rodent (mouse or rat), goat, primate (e.g., monkey), or camel antibody. In one embodiment, the non-human antibody is a rodent (mouse or rat antibody). Methods for making rodent antibodies are known in the art.
[0303] Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Spleen cells from these transgenic mice immunized with an antigen of interest are used to produce hybridomas secreting human mAbs with specific affinity for epitopes from human proteins (see, e.g., Wood et al. International Application No. WO 91 / 00906; Kucherlapati et al. PCT Publication No. WO 91 / 10741; Lonberg et al. International Application No. WO 92 / 03918; Kay et al. International Application No. 92 / 03917; Lonberg et al. 1994 Nature 368:856-859; Green,LL et al. 1994 Nature Genet. 7:13-21; Morrison,SL et al. 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al. 1993 Year Immunol 1999:10:111-112; and, in particular, human mAbs secreted by the human mAb expressing a specific affinity for an epitope from a human protein (see, e.g., Wood et al. International Application No. WO 91 / 00906; Kucherlapati et al. PCT Publication No. WO 91 / 10741; Lonberg et al. International Application No. WO 92 / 03918; Kay et al. International Application No. WO 92 / 03917; Lonberg et al. 1994 Nature 368:856-859; Green,LL et al. 1994 Nature Genet. 7:13-21; Morrison,SL et al. 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al. 1993 Year Immunol 1999:10:111-112). 7:33-40; see Tuaillon et al. 1993 PNAS 90:3720-3724, Bruggeman et al. 1991 Eur J Immunol 21:1323-1326).
[0304] The antibody may be one whose variable region, or a part thereof, such as CDR, is generated in a non-human organism, such as rat or mouse.Chimeric antibodies, CDR-grafted antibodies, and humanized antibodies are within the scope of the present invention.Antibodies that are generated in a non-human organism, such as rat or mouse, and then modified, for example, in variable framework or constant regions to reduce antigenicity in humans, are within the scope of the present invention.
[0305] Chimeric antibodies can be produced by any suitable recombinant DNA technique, several of which are known in the art (Robinson et al., International Patent Publication No. PCT / US86 / 02269; Akira, et al., European Patent Application No. 184,187; Taniguchi, M., European Patent Application No. 171,496; Morrison et al., European Patent Application No. 173,494; Neuberger et al., International Application No. WO 86 / 01533; Cabilly et al. U.S. Pat. No. 4,816,567; Cabilly et al., European Patent Application No. 125,023; Better et al. (1988 Science 240:1041-1043); Liu et al. (1987) PNAS 84:3439-3443; Liu et al. (see, for example, Sun et al., 1987, J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al., 1987, Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shu et al., 1988, J. Natl Cancer Inst. 80:1553-1559).
[0306] A humanized antibody or a CDR-grafted antibody has at least one or two, but generally all three recipient CDRs (of the immunoglobulin heavy and / or light chain) replaced with a donor CDR. The antibody may be replaced with at least a portion of a non-human CDR, or only a portion of the CDRs may be replaced with a non-human CDR. It is only necessary to replace the number of CDRs required for the binding of the humanized antibody to lipopolysaccharide. In one embodiment, the donor is a rodent antibody, e.g., a rat or mouse antibody, and the recipient is a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDRs is called the "donor" and the immunoglobulin providing the framework is called the "acceptor". In one embodiment, the donor immunoglobulin is non-human (e.g., rodent). The acceptor framework is typically a naturally occurring (e.g., human) framework or consensus framework, or a sequence that is about 85% or more, e.g., 90%, 95%, 99% or more identical thereto.
[0307] As used herein, the term "consensus sequence" refers to a sequence formed from the amino acids (or nucleotides) that occur most frequently in a family of related sequences (see, e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987)). In a family of proteins, each position of the consensus sequence is occupied by the amino acid that occurs most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. Consensus framework refers to the framework region in the consensus immunoglobulin sequence.
[0308] Antibodies may be humanized by any suitable method, and several such methods are known in the art (e.g., as described in Morrison, SL, 1985, Science 229:1202-1207; Oi et al., 1986, BioTechniques 4:214; and Queen et al. U.S. Patent Nos. 5,585,089, 5,693,761, and 5,693,762, the entire contents of which are incorporated herein by reference).
[0309] Humanized antibodies or CDR-grafted antibodies can be produced by CDR-grafting or CDR-replacement, where one, two or all CDRs of an immunoglobulin chain can be replaced.See, for example, U.S. Patent No. 5,225,539, Jones et al. 1986 Nature 321:552-525; Verhoeyan et al. 1988 Science 239:1534, Beidler et al. 1988 J. Immunol. 141:4053-4060, Winter, U.S. Patent No. 5,225,539, the contents of which are expressly incorporated herein by reference. Winter describes a CDR-grafting method that can be used to prepare humanized antibodies (UK Patent Application No. GB 2188638A filed March 26, 1987, Winter, U.S. Patent No. 5,225,539), the contents of which are expressly incorporated herein by reference.
[0310] Also provided are humanized antibodies in which specific amino acids are substituted, deleted, or added. Criteria for selecting amino acids from donors are described, for example, in U.S. Patent No. 5,585,089, e.g., columns 12-16 of U.S. Patent No. 5,585,089, the contents of which are incorporated herein by reference. Other techniques for humanizing antibodies are described in Padlan et al. EP 519596 A1, published December 23, 1992.
[0311] In one embodiment, the antibody molecule has a heavy chain constant region selected from, for example, IgG1, IgG2 (e.g., IgG2a), IgG3, IgG4, IgM, IgA1, IgA2, IgD and IgE heavy chain constant regions, in particular, for example, IgG1, IgG2, IgG3 and IgG4 (e.g., human) heavy chain constant regions. In another embodiment, the antibody molecule has a light chain constant region selected from, for example, kappa or lambda (e.g., human) light chain constant regions. The constant region can be modified (e.g., mutated) to modify the properties of the antibody molecule (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, number of cysteine residues, effector cell function, and / or complement function). In one embodiment, the antibody molecule has effector function and can fix complement. In another embodiment, the antibody molecule does not recruit effector cells or does not fix complement. In certain embodiments, the antibody molecule has reduced or no ability to bind to Fc receptors. For example, it may be an isotype or subtype, fragment, or other variant that does not support binding to an Fc receptor, eg, having a mutated or deleted Fc receptor binding region.
[0312] In one embodiment, the constant region of the antibody molecule is modified. Methods for modifying antibody constant regions are known in the art. Antibody molecules with modified functions, such as modified affinity for effector ligands, such as FcR on cells, or the C1 component of complement, can be produced by replacing at least one amino acid residue in the constant part of the antibody with a different residue (e.g., as described in EP 388,151 A1, U.S. Pat. No. 5,624,821 and U.S. Pat. No. 5,648,260, the entire contents of which are incorporated herein by reference). Amino acid mutations that stabilize antibody structure, such as S228P (S241P in EU nomenclature, Kabat nomenclature) in human IgG4, are also contemplated. Similar types of modifications can be described that, when applied to mice or other species, would reduce or eliminate these functions of immunoglobulins.
[0313] In one embodiment, the only amino acids in the antibody molecule are standard amino acids. In one embodiment, the antibody molecule comprises naturally occurring amino acids, their analogs, derivatives, and congeners, amino acid analogs with variant side chains, and / or any stereoisomers of any of the foregoing. The antibody molecule may comprise the D-optical isomer or the L-optical isomer of the amino acids and peptidomimetics.
[0314] The polypeptide of the antibody molecule described herein may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The antibody molecule may also be modified by any other manipulation, such as, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or conjugation with a labeling component. The polypeptide may be isolated from a natural source, produced by recombinant technology from a eukaryotic or prokaryotic host, or may be the product of a synthetic procedure.
[0315] The antibody molecules described herein can be used alone in unconjugated form or can be conjugated to a substance, e.g., a toxin or moiety (e.g., a therapeutic agent, a radioluminescent compound, a molecule of plant, fungal, or bacterial origin, or a biological protein (e.g., a protein toxin) or particle (e.g., a recombinant viral particle, e.g., via a viral coat protein). For example, the antibody molecule can be conjugated to a radioisotope, such as an α-, β-, or γ-emitter, or a β and γ-emitter.
[0316] An antibody molecule may be derivatized or linked to another functional molecule (e.g., another peptide or protein). As used herein, a "derivatized" antibody molecule is an antibody molecule that has been modified. Methods of derivatization include, but are not limited to, the addition of a fluorescent moiety, a radioactive nucleotide, a toxin, an enzyme, or an affinity ligand such as biotin. Thus, antibody molecules are intended to include derivatized and otherwise modified forms of the antibodies described herein, including immunoadhesion molecules. For example, an antibody molecule may be functionally linked (by chemical bond, genetic fusion, non-covalent association, or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or diabody), a detectable agent, a toxin, a pharmaceutical agent, and / or a protein or peptide that can mediate the association of an antibody or an antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
[0317] Some types of derivatized antibody molecules are produced by crosslinking two or more antibodies (either of the same type or of different types, e.g., to create bispecific antibodies). Suitable crosslinkers include heterobifunctional (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl sulfite), which have two distinct reactive groups separated by a suitable spacer. Such linkers are available from Pierce Chemical Company, Rockford, Ill.
[0318] Useful detectable agents with which anti-dengue antibody molecules may be derivatized (or labeled) include fluorescent compounds, various enzymes, prosthetic groups, luminescent materials, bioluminescent materials, fluorescent metal atoms such as europium (Eu) and other anthanides, and radioactive materials (described below). Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5 dimethylamine-1-naphthalenesulfonyl chloride, phycoerythrin, and the like. Antibodies may also be derivatized with detectable enzymes, such as alkaline phosphatase, horseradish peroxidase, β-galactosidase, acetylcholinesterase, glucose oxidase, and the like. When an antibody is derivatized with a detectable enzyme, it is detected by adding additional reagents that are used to generate a detectable reaction product with the enzyme. For example, when the detectable agent horseradish peroxidase is present, the addition of hydrogen peroxide and diaminobenzidine results in a detectable colored reaction product. Antibody molecules may also be derivatized with prosthetic groups (e.g., streptavidin / biotin and avidin / biotin). For example, antibodies may be derivatized with biotin and detected through indirect measurement of avidin or streptavidin binding. Examples of suitable fluorophores include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin, examples of luminescent materials include luminol, and examples of bioluminescent materials include luciferase, luciferin, and aequorin.
[0319] For example, labeled antibody molecules can be used in many contexts, diagnostically and / or experimentally, including: (i) isolating a given antigen by standard techniques such as affinity chromatography or immunoprecipitation; (ii) detecting a given antigen (e.g., in cell lysates or cell supernatants) to assess protein abundance and expression patterns; and (iii) monitoring protein levels in tissues as part of a clinical trial procedure, e.g., to determine the effectiveness of a given therapeutic regimen.
[0320] The antibody molecule may be conjugated to another molecular entity, typically a label or a therapeutic agent (e.g., an antimicrobial (e.g., antibacterial or bactericidal), immunomodulatory, immunostimulatory, cytotoxic, or cytostatic agent) or moiety. Radioisotopes can be used for diagnostic or therapeutic applications. Radioisotopes that can be attached to antibody molecules include, but are not limited to, α-, β-, or γ-emitters, or β and γ-emitters. Such radioisotopes include iodine ( 131 I or 125 I), yttrium ( 90 Y), lutetium ( 177 Lu), Actinium ( 225 Ac), praseodymium, astatine ( 211 At), Rhenium ( 186 Re), Bismuth ( 212 Bi or 213 Bi), Indium ( 111 In), Technetium ( 99 mTc), phosphorus ( 32 P), Rhodium ( 188 Rh), Sulfur ( 35 S), carbon ( 14 C), tritium ( 3 H), Chromium ( 51 Cr), Chlorine ( 36 Cl), Cobalt ( 57 Co or 58 Co), Iron ( 59 Fe), Selenium ( 75 Se) or Gallium ( 67 Radioisotopes useful as therapeutic agents include, but are not limited to, yttrium ( 90 Y), lutetium ( 177 Lu), Actinium ( 225 Ac), praseodymium, astatine ( 211 At), Rhenium ( 186 Re), Bismuth ( 212 Bi or 213 Bi), and rhodium ( 188Radioisotopes useful as labels include, for example, iodine ( 131 I or 125 I), Indium ( 111 In), Technetium ( 99 mTc), phosphorus ( 32 P), carbon ( 14 C), and tritium ( 3 H), or one or more of the therapeutic isotopes listed above.
[0321] In one aspect, the disclosure provides a method of making an IL-2 complex as described herein. The method includes, for example, contacting an IL-2 variant as described herein with an anti-IL-2 antibody molecule (e.g., an anti-IL-2 antibody molecule that binds to the IL-2 variant), thereby generating an IL-2 complex. In one embodiment, the method further includes evaluating the efficacy of the IL-2 complex in vitro, ex vivo, or in vivo.
[0322] The present disclosure provides isolated nucleic acid molecules encoding the IL-2 complexes (or portions thereof) described herein, as well as vectors and host cells thereof. Nucleic acid molecules include, but are not limited to, RNA, genomic DNA, and cDNA.
[0323] IL-2 conjugates In one embodiment, the IL-2 agent comprises a conjugate, eg, an IL-2 conjugate described herein.
[0324] In one embodiment, the IL-2 conjugate comprises an IL-2 variant as described herein and a non-IL-2 moiety. In one embodiment, the IL-2 conjugate comprises one or more amino acid modifications (e.g., substitutions) as described in Table 9. In one embodiment, the IL-2 conjugate comprises an amino acid sequence as described in Table 9, or a functional fragment thereof. In one embodiment, the non-IL-2 moiety comprises an antibody molecule, e.g., an antibody molecule as described herein. In one embodiment, the non-IL-2 moiety comprises a polymer, e.g., a polyether compound. In one embodiment, the polyether compound comprises polyethylene glycol (PEG). In one embodiment, the non-IL-2 moiety comprises a cytokine. The IL-2 variant may be linked to the non-IL-2 moiety directly or indirectly, e.g., via a linker. In one embodiment, the IL-2 conjugate is an IL-2 fusion protein.
[0325] In one embodiment, the IL-2 conjugate is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:1000, SEQ ID NO:1001, SEQ ID NO:1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0326] In one embodiment, the IL-2 conjugate is an immunoconjugate, e.g., comprising an antibody molecule. In one embodiment, the IL-2 variant is bound to the antibody molecule by a covalent bond. In one embodiment, the IL-2 variant is bound to the antibody molecule by a peptide bond. In one embodiment, the IL-2 variant and the antibody molecule form a fusion protein. In one embodiment, the fusion protein comprises a linker between the IL-2 variant and the antibody molecule (e.g., the heavy chain, the light chain, or both). In one embodiment, the IL-2 variant is bound to the antibody molecule by a non-peptide bond. In one embodiment, the IL-2 variant is not bound to the antibody molecule by a non-peptide bond.
[0327] In one embodiment, the IL-2 variant is attached to the backbone of the antibody molecule. In another embodiment, the IL-2 variant is attached to a side chain of the antibody molecule. In one embodiment, the antibody molecule is attached to the backbone of the IL-2 variant. In one embodiment, the antibody molecule is attached to a side chain of the IL-2 variant.
[0328] In one embodiment, two or more (e.g., three, four, five, six, seven, eight, or more) IL-2 variants are conjugated to the antibody molecule. In one embodiment, four IL-2 variants are conjugated to the antibody molecule. For example, the IL-2 variants can be the same, or at least some of the IL-2 variants are different from one another. In one embodiment, the IL-2 variants are conjugated to the antibody molecule in a bivalent manner. In another embodiment, the IL-2 variants are conjugated to the antibody molecule in a trivalent manner.
[0329] In one embodiment, the IL-2 conjugate is produced by enzymatic synthesis. For example, the IL-2 conjugate can be produced by chemical synthesis of an IL-2 variant, expression of an antibody molecule, and enzymatic ligation of the IL-2 variant to the antibody molecule. In one embodiment, a reaction efficiency of 90% or more, e.g., 92% or more, 95% or more, 97% or more, or 99% or more is achieved. In another embodiment, the method further comprises purifying the ADC. In one embodiment, the yield is 60% or more (e.g., 70% or more, 75% or more, 80% or more, 90% or more, or 95% or more) after purification.
[0330] In one aspect, the disclosure provides a combination of (a) an immunoconjugate comprising a first antibody molecule with reduced effector function as described herein and an IL-2 variant, and (b) a second antibody molecule with increased effector function for use in the treatment of a disorder, such as, for example, a disorder described herein.
[0331] In one embodiment, the reduction in effector function of the first antibody comprises a reduction in binding to an activating Fc receptor, a reduction in ADCC, a reduction in ADCP, a reduction in CDC, a reduction in cytokine secretion, or a combination thereof. In one embodiment, the reduction in effector function is a reduction in binding to an activating Fc receptor, for example, a human Fc receptor. In one embodiment, the activating Fc receptor is a Fey receptor. In one embodiment, the activating Fc receptor is FcγRIIIa, FcγRI, or FcγRIIa. In one embodiment, the reduction in effector function comprises a reduction in ADCC. In one embodiment, the increase in effector function comprises a reduction in binding to an activating Fc receptor and a reduction in ADCC.
[0332] In one embodiment, the first antibody molecule comprises one or more amino acid mutations (e.g., substitutions) in the Fc region described herein. In one embodiment, the first antibody molecule comprises an amino acid substitution at position P329 of the immunoglobulin heavy chain. In one embodiment, the amino acid substitution comprises P329A or P329G, e.g., P329G. In one embodiment, the antibody molecule comprises an additional amino acid substitution at positions S228, E233, L234, L235, N297, P331, or a combination thereof, of the immunoglobulin heavy chain. In one embodiment, the additional amino acid substitution comprises S228P, E233P, L234A, L235A, L235E, N297A, N297D, P331S, or a combination thereof. In a particular embodiment, the antibody comprises an amino acid substitution at positions P329, L234, and L235 of the immunoglobulin heavy chain. In one embodiment, the amino acid substitutions include L234A, L235A and P329G (LALA P329G).
[0333] In one embodiment, the first antibody molecule is directed to an antigen present on tumor cells or in the tumor cell environment. In one embodiment, the first antibody is directed to an antigen selected from fibroblast activation protein (FAP), A1 domain of tenascin-C (TNC A1), A2 domain of tenascin-C (TNC A2), extra domain B of fibronectin (EDB), carcinoembryonic antigen (CEA), and melanoma-associated chondroitin sulfate proteoglycan (MCSP).
[0334] In one embodiment, the increased effector function of the second antibody molecule comprises increased binding to an activating Fc receptor, increased ADCC, increased ADCP, increased CDC, increased cytokine secretion, or a combination thereof. In one embodiment, the increased effector function comprises increased binding to an activating Fc receptor. In one embodiment, the activating Fc receptor is FcγRIIIa, FcγRI, or FcγRIIa. In one embodiment, the increased effector function comprises increased ADCC. In one embodiment, the increased effector function comprises increased binding to an activating Fc receptor and increased ADCC.
[0335] In one embodiment, the second antibody molecule comprises one or more amino acid mutations (e.g., substitutions) in the Fc region. In one embodiment, the second antibody molecule comprises modified glycosylation in the Fc region. In one embodiment, the modified glycosylation in the Fc region comprises an increase in the proportion of non-fucosylated oligosaccharides in the Fc region compared to the unmodified antibody molecule (e.g., an increase of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%). In one embodiment, the modification comprises an increase in the proportion of bisected oligosaccharides in the Fc region compared to the unmodified antibody molecule (e.g., an increase of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%). In one embodiment, modified glycosylation in the Fc region comprises an increase in the proportion of bisected, non-fucosylated oligosaccharides in the Fc region (e.g., an increase of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%) compared to an unmodified antibody molecule.
[0336] In one embodiment, the second antibody molecule is directed to an antigen present on a tumor cell, hi one embodiment, the second antibody molecule is directed to an antigen selected from CD20, epidermal growth factor receptor (EGFR), HER2, HER3, insulin-like growth factor receptor (IGF-1R), c-Met, CUB domain-containing protein-1 (CDCP1), carcinoembryonic antigen (CEA), and melanoma-associated chondroitin sulfate proteoglycan (MCSP).
[0337] In one embodiment, the disease is a disorder treatable by stimulation of effector cell function. In one aspect, the disclosure provides a composition comprising: (a) an immunoconjugate comprising a first antibody molecule with reduced effector function and an IL-2 variant described herein; (b) a second antibody molecule with increased effector function; and (c) a pharma- ceutically acceptable carrier.
[0338] IL-2 receptor The IL-2 agents described herein (e.g., IL-2 variants, IL-2 fusion proteins, IL-2 complexes, or IL-2 conjugates) can bind to the IL-2 receptor (IL-2R) and / or modulate one or more functions associated with the IL-2R.
[0339] IL-2R is a heterotrimeric protein expressed on the surface of certain immune cells, such as lymphocytes, that bind and respond to IL-2. IL-2 receptors typically have three forms generated by different combinations of three different chains: α (alpha) (also known as IL-2Rα, CD25, or Tac antigen), β (beta) (also known as IL-2Rβ, or CD122), and γ (gamma) (also known as IL-2Rγ, γc, common gamma chain, or CD132).
[0340] The IL-2R chains are expressed separately and differentially on various cell types and can be assembled in different combinations and orders to generate low, intermediate, and high affinity IL-2R. IL-2Rα binds IL-2 with low affinity, IL-2Rβ and IL-2Rγ together form a complex that binds IL-2 with intermediate affinity (e.g., on memory T cells and NK cells), and IL-2Rα, IL-2Rβ, and IL-2Rγ together form a complex that binds IL-2 with high affinity (e.g., on activated T cells and regulatory T cells).
[0341] IL-2Rβ and IL-2Rγ complex with Janus kinase 1 (JAK1) and Janus kinase 3 (JAK3), respectively. Binding of IL-2 to IL-2R can activate JAK1 / JAK2 and initiate downstream intracellular signaling, such as the MAP kinase pathway, the phosphoinositide 3 kinase (PI3K) pathway, or the JAK-STAT pathway (Liao et al., Curr Opin Immunol. 2011; 23(5): 598-604; Malek and Castro. Immunity. 2010;33(2):153-165).
[0342] IL-2R plays an important role in the immune system, tolerance, and immunity. For example, the interaction between IL-2 and IL-2R is involved in promoting the differentiation of certain immature T cells into regulatory T cells, and the differentiation of T cells into effector T cells, and into memory T cells. The interaction between IL-2 and IL-2R is also associated with autoimmune diseases, infection, and cell-mediated immunity.
[0343] In one aspect, the disclosure provides an IL-2 agent comprising an IL-2 variant described herein having altered binding affinity to an IL-2R, e.g., one, two, or all of IL-2Rα, IL-Rβ, or IL-2Rγ. For example, an IL-2 variant can have one or more (e.g., two, three, four, five, or more) amino acid modifications (e.g., substitutions or mutations) that affect the interaction between IL-2 and IL-2R, e.g., one, two, or all of IL-2Rα, IL-Rβ, or IL-2Rγ.
[0344] In one embodiment, the IL-2 agent has an altered (e.g., reduced) binding affinity to IL-2Rα. In one embodiment, the binding affinity to IL-2Rα is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant. In one embodiment, the IL-2 agent has an altered (e.g., reduced) binding affinity to IL-2Rβ. In one embodiment, the binding affinity to IL-2Rβ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant. In one embodiment, the IL-2 agent has an altered (e.g., reduced) binding affinity to IL-2Rγ. In one embodiment, the binding affinity to IL-2Rγ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to an IL-2 agent that comprises wild-type IL-2 or an IL-2 agent that comprises a reference IL-2 variant.
[0345] In one embodiment, the IL-2 agent has an altered (e.g., reduced) binding affinity to IL-2Rα and an altered (e.g., reduced) binding affinity to IL-2Rβ. In one embodiment, the binding affinity to IL-2Rα is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, and the binding affinity to IL-2Rβ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In one embodiment, the binding affinity to IL-2Rα and IL-2Rβ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant.
[0346] In one embodiment, the IL-2 agent has an altered (e.g., reduced) binding affinity to IL-2Rα and an altered (e.g., reduced) binding affinity to IL-2Rγ. In one embodiment, the binding affinity to IL-2Rα is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, and the binding affinity to IL-2Rγ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In one embodiment, the binding affinity to IL-2Rα and IL-2Rγ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant.
[0347] In one embodiment, the IL-2 agent has an altered (e.g., reduced) binding affinity to IL-2Rβ and an altered (e.g., reduced) binding affinity to IL-2Rγ. In one embodiment, the binding affinity to IL-2Rβ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, and the binding affinity to IL-2Rγ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In one embodiment, the binding affinity to IL-2Rβ and IL-2Rγ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant.
[0348] In one embodiment, the IL-2 agent has altered (e.g., reduced) binding affinity to IL-2Rα, altered (e.g., reduced) binding affinity to IL-2Rβ, and altered (e.g., reduced) binding affinity to IL-2Rγ. In one embodiment, the binding affinity to IL-2Rα is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, the binding affinity to IL-2Rβ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, and the binding affinity to IL-2Rγ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In one embodiment, the binding affinity to IL-2Rα, IL-2Rβ, and IL-2Rγ is reduced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to an IL-2 agent that comprises wild-type IL-2 or an IL-2 agent that comprises a reference IL-2 variant.
[0349] In one embodiment, the binding affinity of an IL-2 agent provided by the present disclosure to any of IL-2Rα, IL-2Rβ, or IL-2Rγ is reduced, but not abolished. For example, the reduction can be in the range of about 10% to about 90%, e.g., about 20% to about 80%, about 30% to about 70%, about 40% to about 60%, about 10% to about 50%, or about 50% to about 90%, as compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant.
[0350] Fc area The present disclosure provides an IL-2 agent (e.g., an IL-2 variant, fusion polypeptide, complex, or immunoconjugate) that includes an Fc region or fragment thereof described herein, e.g., an Fc region or fragment thereof (e.g., a functional fragment thereof).
[0351] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein and an Fc region described herein. In one embodiment, the IL-2 agent further comprises a linker between the IL-2 variant and the Fc region. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein comprising an Fc region described herein. In one embodiment, the Fc region comprises one or more mutations described herein.
[0352] Fragment crystallizable region, or Fc region, refers to the region of an immunoglobulin that interacts with Fc receptors. In one embodiment, the Fc region interacts with proteins of the complement system. Without wishing to be bound by theory, in one embodiment, it is believed that the interaction between the Fc region and the Fc receptor allows for activation of the immune system.
[0353] In IgG, IgA, and IgD antibody isotypes, naturally occurring Fc regions generally comprise two identical protein fragments derived from the second and third constant domains of the antibody's two heavy chains. Naturally occurring IgM and IgE Fc regions generally comprise three heavy chain constant domains (C H The Fc region of IgG contains highly conserved N-glycosylation sites (Stadlmann et al. (2008). Proteomics 8 (14): 2858-2871; Stadlmann (2009) Proteomics 9 (17): 4143-4153). Without wishing to be bound by theory, in one embodiment, glycosylation of the Fc fragment is believed to contribute to Fc receptor-mediated activity (Peipp et al. (2008) Blood 112(6):2390-2399). In one embodiment, the N-glycans attached to this site are predominantly complex type core fucosylated biantennary structures. In another embodiment, a small proportion of these N-glycans also contain bisecting GlcNAc and / or α-2,6 linked sialic acid residues.
[0354] An exemplary fragment of the Fc region amino acid sequence from human IgG1 is provided in SEQ ID NO:40, and is shown below. DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVL H QDWLNGKEYKCKVSNKALAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL H N H YTQKSLSLSPGK (SEQ ID NO:40)
[0355] In SEQ ID NO:40, the first amino acid residue in this sequence is referred to herein as position 221. The three histidine residues shown in bold and underlined are at positions 310, 433, and 435, respectively.
[0356] An IL-2 agent comprising an Fc region or fragment thereof (e.g., an IL-2-Fc fusion protein) described herein can have one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) of the mutations or combinations of mutations described in Table 1 (e.g., according to EU numbering). [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]
[0357] In one embodiment, the Fc region comprises FcMut001. In one embodiment, the Fc region comprises FcMut002. In one embodiment, the Fc region comprises FcMut003. In one embodiment, the Fc region comprises FcMut004. In one embodiment, the Fc region comprises FcMut005. In one embodiment, the Fc region comprises FcMut006. In one embodiment, the Fc region comprises FcMut007. In one embodiment, the Fc region comprises FcMut008. In one embodiment, the Fc region comprises FcMut009. In one embodiment, the Fc region comprises FcMut010. In one embodiment, the Fc region comprises FcMut011. In one embodiment, the Fc region comprises FcMut012. In one embodiment, the Fc region comprises FcMut013. In one embodiment, the Fc region comprises FcMut014. In one embodiment, the Fc region comprises FcMut015. In one embodiment, the Fc region comprises FcMut016. In one embodiment, the Fc region comprises FcMut017. In one embodiment, the Fc region comprises FcMut018. In one embodiment, the Fc region comprises FcMut019. In one embodiment, the Fc region comprises FcMut020. In one embodiment, the Fc region comprises FcMut021. In one embodiment, the Fc region comprises FcMut022. In one embodiment, the Fc region comprises FcMut023. In one embodiment, the Fc region comprises FcMut024. In one embodiment, the Fc region comprises FcMut026. In one embodiment, the Fc region comprises FcMut027. In one embodiment, the Fc region comprises FcMut028. In one embodiment, the Fc region comprises FcMut029. In one embodiment, the Fc region comprises FcMut030. In one embodiment, the Fc region comprises FcMut031. In one embodiment, the Fc region comprises FcMut032. In one embodiment, the Fc region comprises FcMut033. In one embodiment, the Fc region comprises FcMut034. In one embodiment, the Fc region comprises FcMut035. In one embodiment, the Fc region comprises FcMut036. In one embodiment, the Fc region comprises FcMut037. In one embodiment, the Fc region comprises FcMut038. In one embodiment, the Fc region comprises FcMut039.In one embodiment, the Fc region comprises FcMut040. In one embodiment, the Fc region comprises FcMut041. In one embodiment, the Fc region comprises FcMut042. In one embodiment, the Fc region comprises FcMut043. In one embodiment, the Fc region comprises FcMut044. In one embodiment, the Fc region comprises FcMut045. In one embodiment, the Fc region comprises FcMut046. In one embodiment, the Fc region comprises FcMut047. In one embodiment, the Fc region comprises FcMut048. In one embodiment, the Fc region comprises FcMut049. In one embodiment, the Fc region comprises FcMut050. In one embodiment, the Fc region comprises FcMut051. In one embodiment, the Fc region comprises FcMut052. In one embodiment, the Fc region comprises FcMut053. In one embodiment, the Fc region comprises FcMut067. In one embodiment, the Fc region comprises FcMut068. In one embodiment, the Fc region comprises FcMut069. In one embodiment, the Fc region comprises FcMut070. In one embodiment, the Fc region comprises FcMut071. In one embodiment, the Fc region comprises FcMut072. In one embodiment, the Fc region comprises FcMut073. In one embodiment, the Fc region comprises FcMut074. In one embodiment, the Fc region comprises FcMut075. In one embodiment, the Fc region comprises FcMut076. In one embodiment, the Fc region comprises FcMut077. In one embodiment, the Fc region comprises FcMut078. In one embodiment, the Fc region comprises FcMut079. In one embodiment, the Fc region comprises FcMut080. In one embodiment, the Fc region comprises FcMut081. In one embodiment, the Fc region comprises FcMut082. In one embodiment, the Fc region comprises FcMut083. In one embodiment, the Fc region comprises FcMut084. In one embodiment, the Fc region comprises FcMut085. In one embodiment, the Fc region comprises FcMut086. In one embodiment, the Fc region comprises FcMut087. In one embodiment, the Fc region comprises FcMut088. In one embodiment, the Fc region comprises FcMut089. In one embodiment, the Fc region comprises FcMut090.In one embodiment, the Fc region comprises FcMut091. In one embodiment, the Fc region comprises FcMut093. In one embodiment, the Fc region comprises FcMut094. In one embodiment, the Fc region comprises FcMut095. In one embodiment, the Fc region comprises FcMut096. In one embodiment, the Fc region comprises FcMut097. In one embodiment, the Fc region comprises FcMut098. In one embodiment, the Fc region comprises FcMut099. In one embodiment, the Fc region comprises FcMut100. In one embodiment, the Fc region comprises FcMut101. In one embodiment, the Fc region comprises FcMut102. In one embodiment, the Fc region comprises FcMut103. In one embodiment, the Fc region comprises FcMut104. In one embodiment, the Fc region comprises FcMut105. In one embodiment, the Fc region comprises FcMut106. In one embodiment, the Fc region comprises FcMut107. In one embodiment, the Fc region comprises FcMut108. In one embodiment, the Fc region comprises FcMut109. In one embodiment, the Fc region comprises FcMut110. In one embodiment, the Fc region comprises FcMut111. In one embodiment, the Fc region comprises FcMut112. In one embodiment, the Fc region comprises FcMut113. In one embodiment, the Fc region comprises FcMut114. In one embodiment, the Fc region comprises FcMut115. In one embodiment, the Fc region comprises FcMut116. In one embodiment, the Fc region comprises FcMut117. In one embodiment, the Fc region comprises FcMut118. In one embodiment, the Fc region comprises FcMut119. In one embodiment, the Fc region comprises FcMut120. In one embodiment, the Fc region comprises FcMut121. In one embodiment, the Fc region comprises FcMut122. In one embodiment, the Fc region comprises FcMut123. In one embodiment, the Fc region comprises FcMut124. In one embodiment, the Fc region comprises FcMut125. In one embodiment, the Fc region comprises FcMut126. In one embodiment, the Fc region comprises FcMut127. In one embodiment, the Fc region comprises FcMut128. In one embodiment, the Fc region comprises FcMut129.In one embodiment, the Fc region comprises FcMut130. In one embodiment, the Fc region comprises FcMut131. In one embodiment, the Fc region comprises FcMut132. In one embodiment, the Fc region comprises FcMut133. In one embodiment, the Fc region comprises FcMut134. In one embodiment, the Fc region comprises FcMut135. In one embodiment, the Fc region comprises FcMut136. In one embodiment, the Fc region comprises FcMut137. In one embodiment, the Fc region comprises FcMut138. In one embodiment, the Fc region comprises FcMut139. In one embodiment, the Fc region comprises FcMut140. In one embodiment, the Fc region comprises FcMut141. In one embodiment, the Fc region comprises FcMut142. In one embodiment, the Fc region comprises FcMut143. In one embodiment, the Fc region comprises FcMut144. In one embodiment, the Fc region comprises FcMut145. In one embodiment, the Fc region comprises FcMut146. In one embodiment, the Fc region comprises FcMut147. In one embodiment, the Fc region comprises FcMut148. In one embodiment, the Fc region comprises FcMut149. In one embodiment, the Fc region comprises FcMut150. In one embodiment, the Fc region comprises FcMut151. In one embodiment, the Fc region comprises FcMut152. In one embodiment, the Fc region comprises FcMut153. In one embodiment, the Fc region comprises FcMut154. In one embodiment, the Fc region comprises FcMut155. In one embodiment, the Fc region comprises FcMut156. In one embodiment, the Fc region comprises FcMut157. In one embodiment, the Fc region comprises FcMut158. In one embodiment, the Fc region comprises FcMut159. In one embodiment, the Fc region comprises FcMut160. In one embodiment, the Fc region comprises FcMut161. In one embodiment, the Fc region comprises FcMut162. In one embodiment, the Fc region comprises FcMut163. In one embodiment, the Fc region comprises FcMut164. In one embodiment, the Fc region comprises FcMut165. In one embodiment, the Fc region comprises FcMut166. In one embodiment, the Fc region comprises FcMut167.In one embodiment, the Fc region comprises FcMut168. In one embodiment, the Fc region comprises FcMut169. In one embodiment, the Fc region comprises FcMut170. In one embodiment, the Fc region comprises FcMut171. In one embodiment, the Fc region comprises FcMut172. In one embodiment, the Fc region comprises FcMut173. In one embodiment, the Fc region comprises FcMut174. In one embodiment, the Fc region comprises FcMut175. In one embodiment, the Fc region comprises FcMut176. In one embodiment, the Fc region comprises FcMut177. In one embodiment, the Fc region comprises FcMut178. In one embodiment, the Fc region comprises FcMut179. In one embodiment, the Fc region comprises FcMut180. In one embodiment, the Fc region comprises FcMut181. In one embodiment, the Fc region comprises FcMut182. In one embodiment, the Fc region comprises FcMut183. In one embodiment, the Fc region comprises FcMut184. In one embodiment, the Fc region comprises FcMut185. In one embodiment, the Fc region comprises FcMut186. In one embodiment, the Fc region comprises FcMut187. In one embodiment, the Fc region comprises FcMut188. In one embodiment, the Fc region comprises FcMut189. In one embodiment, the Fc region comprises FcMut190. In one embodiment, the Fc region comprises FcMut191. In one embodiment, the Fc region comprises FcMut192. In one embodiment, the Fc region comprises FcMut193. In one embodiment, the Fc region comprises FcMut194. In one embodiment, the Fc region comprises FcMut195. In one embodiment, the Fc region comprises FcMut196. In one embodiment, the Fc region comprises FcMut197. In one embodiment, the Fc region comprises FcMut198. In one embodiment, the Fc region comprises FcMut199. In one embodiment, the Fc region comprises FcMut200. In one embodiment, the Fc region comprises FcMut201. In one embodiment, the Fc region comprises FcMut202. In one embodiment, the Fc region comprises FcMut203. In one embodiment, the Fc region comprises FcMut204. In one embodiment, the Fc region comprises FcMut205.In one embodiment, the Fc region comprises FcMut206. In one embodiment, the Fc region comprises FcMut207. In one embodiment, the Fc region comprises FcMut208. In one embodiment, the Fc region comprises FcMut209. In one embodiment, the Fc region comprises FcMut210. In one embodiment, the Fc region comprises FcMut211. In one embodiment, the Fc region comprises FcMut212. In one embodiment, the Fc region comprises FcMut213. In one embodiment, the Fc region comprises FcMut214. In one embodiment, the Fc region comprises FcMut215. In one embodiment, the Fc region comprises FcMut216. In one embodiment, the Fc region comprises FcMut217. In one embodiment, the Fc region comprises FcMut218. In one embodiment, the Fc region comprises FcMut219. In one embodiment, the Fc region comprises FcMut220. In one embodiment, the Fc region comprises FcMut221. In one embodiment, the Fc region comprises FcMut222. In one embodiment, the Fc region comprises FcMut223. In one embodiment, the Fc region comprises FcMut224. In one embodiment, the Fc region comprises FcMut225. In one embodiment, the Fc region comprises FcMut226. In one embodiment, the Fc region comprises FcMut227. In one embodiment, the Fc region comprises FcMut228. In one embodiment, the Fc region comprises FcMut229. In one embodiment, the Fc region comprises FcMut230. In one embodiment, the Fc region comprises FcMut231. In one embodiment, the Fc region comprises FcMut232. In one embodiment, the Fc region comprises FcMut233. In one embodiment, the Fc region comprises FcMut234. In one embodiment, the Fc region comprises FcMut242. In one embodiment, the Fc region comprises FcMut243. In one embodiment, the Fc region comprises FcMut244.
[0358] In one embodiment, the Fc region comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or more) mutations or combinations of mutations selected from FcMut045, FcMut171, FcMut183, FcMut186, FcMut190, FcMut197, FcMut213, FcMut215, FcMut216, FcMut219, FcMut222, FcMut223, FcMut224, FcMut226, FcMut227, FcMut228, or FcMut229. In one embodiment, the Fc region comprises one or more (e.g., 2, 3, 4, 5, 6, or all) of a mutation or combination of mutations selected from FcMut045, FcMut183, FcMut197, FcMut213, FcMut215, FcMut228, or FcMut156. In another embodiment, the Fc region comprises one or more (e.g., 2, 3, 4, 5, or all) of a mutation or combination of mutations selected from FcMut183, FcMut197, FcMut213, FcMut215, FcMut228, or FcMut229.
[0359] In one embodiment, the Fc region does not include one or more (e.g., two, three, four, or all) of a mutation or combination of mutations selected from FcMut018, FcMut021, FcMut050, FcMut102, or YTE. In one embodiment, the Fc region includes one or more (e.g., two, three, four, or all) of a mutation or combination of mutations selected from FcMut018, FcMut021, FcMut050, FcMut102, or YTE, and one or more other mutations or combinations of mutations set forth in Table 1.
[0360] In one embodiment, the Fc region comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) of the mutations or combinations of mutations set forth in Table 1 that result in a synergistic effect (e.g., binding affinity or circulating half-life) as described herein.
[0361] In one embodiment, the Fc region comprises one or more (e.g., 2, 3, 4, 5, 6, or 7) mutations at residues selected from T256, H285, N286, T307, Q311, N315, or A378. In one embodiment, the Fc region comprises one or more (e.g., 2, 3, 4, 5, 6, or 7) mutations selected from T256D, H285N, N286D, T307Q, Q311V, N315D, or A378V.
[0362] In one embodiment, the Fc region comprises mutations that enhance half-life, mutations that can disrupt Fc effector function, or both. In one embodiment, the Fc region comprises one or more mutations or combinations of mutations described herein, e.g., selected from M252W, V308F / N434Y, R255Y, P257L / N434Y, V308F, P257N / M252Y, G385N, P257N / V308Y, N434Y, M252Y / S254T / T256E ("YTE"), M428L / N434S ("LS"), or any combination thereof. Alternatively, or additionally, in one embodiment, the Fc region comprises (a) a combination of one or more (e.g., 2, 3, 4, 5 or more) mutations selected from T256D / Q311V / A378V, H285N / T307Q / N315D, H285D / T307Q / A378V, T307Q / Q311V / A378V, T256D / N286D / T307R / Q311V / A378V, or T256D / T307R / Q311V; (b) a mutation or combination of mutations capable of disrupting an Fc effector function, e.g., N297G, L234A / L235A (also known as "LALA" mutations), L234A / L235A / P329G (also known as "LALAPG" mutations), or (c) both (a) and (b).
[0363] In one embodiment, the Fc region comprises the mutations T256D / Q311V / A378V and a mutation or combination of mutations capable of disrupting Fc effector function, such as, for example, L234A / L235A. In one embodiment, the Fc region comprises the mutations H285N / T307Q / N315D and a mutation or combination of mutations capable of disrupting Fc effector function, such as, for example, L234A / L235A. In one embodiment, the Fc region comprises the mutations H285D / T307Q / A378V and a mutation or combination of mutations capable of disrupting Fc effector function, such as, for example, L234A / L235A. In one embodiment, the Fc region comprises the mutations T307Q / Q311V / A378V and a mutation or combination of mutations capable of disrupting Fc effector function, such as, for example, L234A / L235A. In one embodiment, the Fc region comprises the mutations T256D / N286D / T307R / Q311V / A378V and a mutation or combination of mutations capable of disrupting Fc effector function, such as, for example, L234A / L235A. In one embodiment, the Fc region comprises the mutations T256D / T307R / Q311V and a mutation or combination of mutations capable of disrupting Fc effector function, such as, for example, L234A / L235A. Other exemplary Fc mutations are described, for example, in International Application Publication No. WO2018 / 052556, U.S. Application Publication No. US2018 / 0037634, and Booth et al. MAbs. 2018; 10(7): 1098-1110, the contents of which are incorporated by reference in their entireties.
[0364] In one embodiment, the Fc region comprises an Fc region of human IgG1, e.g., human IgG1 m3 allotype. In one embodiment, the Fc region comprises the mutation N297G. In one embodiment, the Fc region comprises an Fc region of human IgG1 allotype m3, human IgG1 allotype m3 comprising the mutation N297G, and / or other mutations of the Fc region of human IgG1 allotype m3, or fragments thereof. In one embodiment, the Fc region comprises the sequence of SEQ ID NO: 1003, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or an amino acid sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.
[0365] Any of the mutations in the Fc region that extend half-life described herein can be used in combination with any Fc mutation that can enhance or abolish Fc effector function.
[0366] In one embodiment, the Fc region comprises a human IgG4 Fc region, a human IgG4 containing a S228P mutation and / or a R409K mutation, and / or other mutations of the human IgG4 Fc region, or a fragment thereof. An exemplary fragment of an Fc region amino acid sequence from human IgG4 is provided in SEQ ID NO:44 and shown below. E 219 SKYGPPCP P 228 CPAPEFLGGPSV 240 FLFPPKPKDT 250 LMISRTPEVT 260 CVVVDVSQED 270 PEVQFNWYVD 280 GVEVHNAKTK 290 PREEQFNSTY 300 RVVSVL T 307 VLH Q 311 DWLNGKEYK 320 CKVSNKGLPS 330SIEGTISKAK 340 GQPREPQVYT 350 LPPSQEEMTK 360 NQVSLTCLVK 370 GFYPSDI A 378 VEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:44)
[0367] In SEQ ID NO: 44, the first amino acid residue in this sequence is referred to herein as position 219. The mutations described to extend the half-life of human IgG1 can be applied to human IgG4 Fc. For example, Mut215 corresponds to the mutations T307Q / Q311V / A378V in SEQ ID NO: 44.
[0368] The Fc region can bind to various cell receptors (e.g., Fc receptors) and complement proteins. The Fc region can also mediate different physiological effects of antibody molecules, such as detection of opsonized particles, cell lysis, degranulation of mast cells, basophils, and eosinophils, and other processes.
[0369] There are several different types of Fc receptors (FcR), which can be classified based on the type of antibody they recognize.
[0370] Fcγ receptors (FcγR) belong to the immunoglobulin superfamily and are involved, for example, in inducing phagocytosis of opsonized microorganisms. This family includes several members, FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA (CD16a), and FcγRIIIB (CD16b), which differ in antibody affinity due to their different molecular structures. For example, FcγRI can bind IgG more strongly than FcγRII or FcγRIII. FcγRI also has an extracellular portion that contains three immunoglobulin (Ig)-like domains and has one more domain than FcγRII or FcγRIII. This property allows FcγRI to bind to only one IgG molecule (or monomer), whereas Fcγ receptors generally need to bind to multiple IgG molecules in an immune complex to be activated.
[0371] Fcγ receptors vary in their affinity for IgG, and different IgG subclasses may have unique affinities for each of the Fcγ receptors. These interactions can be further regulated by glycans (oligosaccharides) at specific positions of IgG. For example, by creating steric hindrance, the fucose-containing CH2-84.4 glycan reduces IgG affinity for FcγRIIIA, while the G0 glycan, which lacks galactose and terminates instead of a GlcNAc moiety, has increased affinity for FcγRIIIA (Maverakis et al. (2015) Journal of Autoimmunity 57(6):1-13).
[0372] The neonatal Fc receptor (FcRn) is expressed on multiple cell types and is structurally similar to MHC class I. This receptor also binds IgG and is involved in the storage of this antibody (Zhu et al. (2001). Journal of Immunology 166 (5): 3266-76.). FcRn is also involved in the transfer of IgG from mother to fetus across the placenta or to breast-fed infants. This receptor may also play a role in the homeostasis of IgG serum levels.
[0373] FcαRI (or CD89) belongs to the FcαR subgroup. FcαRI is present on the surface of neutrophils, eosinophils, monocytes, macrophages (including Kupffer cells), and dendritic cells. It contains two extracellular Ig-like domains and is a member of both the immunoglobulin superfamily and the multichain immune recognition receptor (MIRR) family. It signals by associating with two FcRγ signaling chains.
[0374] The Fc-alpha / mu receptor (Fcα / μR) is a type I transmembrane protein. It can bind IgA but has a higher affinity for IgM (Shibuya and Honda (2006) Springer Seminars in Immunopathology 28 (4): 377-82). This Fc receptor, which has a single Ig-like domain in its extracellular portion, is also a member of the immunoglobulin superfamily.
[0375] There are two known types of FcεR. The high affinity receptor FcεRI is a member of the immunoglobulin superfamily (having two Ig-like domains). FcεRI is found on epidermal Langerhans cells, eosinophils, mast cells, and basophils. This receptor may play a role in controlling allergic responses. FcεRI is also expressed on antigen-presenting cells and controls the production of immune mediators, such as cytokines that promote inflammation (von Bubnoff et al. (2003) Clinical and Experimental Dermatology 28(2):184-7). The low affinity receptor FcεRII (CD23) is a C-type lectin. FcεRII has multiple functions as a membrane-bound or soluble receptor. It can also control the growth and differentiation of B cells and block IgE binding on eosinophils, monocytes, and basophils (Kikutani et al. (1989) Ciba Foundation Symposium 147:23-31).
[0376] In one embodiment, the Fc region can be engineered to contain an antigen binding site to generate an Fcab fragment (Wozniak-Knopp et al. (2010) Protein Eng Des 23(4):289-297). The Fcab fragment can be inserted into a complete immunoglobulin by replacing the Fc region, thus obtaining a bispecific antibody (having both a Fab region and an Fcab region containing separate binding sites).
[0377] The binding and recycling of FcRn can be exemplified as follows. For example, IgG and albumin are internalized into vascular endothelial cells via pinocytosis. The pH of endosomes is 6.0, which promotes the association with membrane-bound FcRn. Endosomal contents can be disposed of in one of two ways: either recycling to the apical plasma membrane or transcytosis from the apical to the basolateral side. IgG that does not associate with FcRn is degraded by lysosomes.
[0378] Without wishing to be bound by theory, it is believed that FcRn interaction with IgG is mediated through Fc. The binding of Fc to FcRn is pH specific, e.g., there is no significant binding at pH 7.4 and no strong binding in acidic environments. The structure of FcRn complexed with the Fc domain of an IgG1 molecule is described, for example, in FIG. 1 of International Application Publication No. WO2018 / 052556 or US Patent Application Publication No. US2018 / 0037634. Each FcRn molecule generally binds to an Fc-monomer. In one embodiment, the Fab domain can also affect the binding of IgG to FcRn, e.g., negatively affecting or not affecting the affinity of IgG to FcRn.
[0379] When the Fc region is engineered to enhance the half-life of a polypeptide, there may be multiple considerations. For example, the extension of the half-life and efficient recycling of an antibody molecule or fusion protein often requires pH-specific affinity enhancement (e.g., only at the low pH of the endosome). FcRn binds proximal to the linker region between the CH2 and CH3 domains of the Fc region. Modifications to the linker may affect Fc engagement with the Fcγ receptor. Modifications on the Fc region may affect the thermal stability and aggregation properties of the polypeptide.
[0380] Pharmaceutical Compositions and Kits The disclosure provides compositions, eg, pharmaceutical compositions, comprising an IL-2 agent described herein, and optionally a pharma- ceutically acceptable carrier.
[0381] As used herein, "pharmaceutical acceptable carriers" include any and all physiologically compatible solvents, dispersion media, isotonicity agents, absorption delaying agents, and the like. The carriers may be suitable for intravenous, intramuscular, subcutaneous, parenteral, rectal, spinal, or epidermal administration (e.g., by injection or infusion). In one embodiment, less than about 5% of the IL-2 agent in the composition is present as aggregates, e.g., less than about 4%, 3%, 2%, or 1%. In one embodiment, at least about 95% of the IL-2 agent in the composition is present as a monomer, e.g., at least about 96%, 97%, 98%, 98.5%, 99%, 99.5%, 99.8%, or more. In one embodiment, at least about 95% of the IL-2 agent in the composition is present as a dimer, e.g., at least about 96%, 97%, 98%, 98.5%, 99%, 99.5%, 99.8%, or more. In one embodiment, the level of aggregates, dimers, or monomers is determined by chromatography, e.g., high performance liquid chromatography size exclusion chromatography (HPLC-SEC). In one embodiment, the IL-2 agent is formulated with a pharma- ceutically acceptable carrier.
[0382] The compositions described herein may be in various forms. These include, for example, liquid, semi-solid, and solid dosage forms, such as liquid solutions (e.g., injection solutions and injectable solutions), dispersions or suspensions, liposomes, and suppositories. The suitable form depends on the intended mode of administration and therapeutic application. Typical suitable compositions are in the form of injection or infusion solutions. One suitable mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In one embodiment, the IL-2 agent is administered by intravenous infusion or injection. In another embodiment, the IL-2 agent is administered by intramuscular or subcutaneous injection. In one embodiment, the IL-2 agent is administered subcutaneously (e.g., presented in an autoinjector or prefilled syringe).
[0383] The terms "parenteral administration" and "administered parenterally" as used herein refer to modes of administration other than enteral administration and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, intrathecal, intraspinal, epidural and intrasternal injection and infusion.
[0384] Pharmaceutical compositions (e.g., for therapeutic use) should typically be sterile and stable under the conditions of manufacture and storage. The compositions may be formulated as solutions, microemulsions, dispersions, liposomes, or other ordered structures suitable for high antibody concentrations. Sterile injectable solutions can be prepared by incorporating the active compound (i.e., antibody or antibody portion) in the required amount in an appropriate solvent with one or a combination of ingredients listed above, as needed, followed by filtered sterilization. In general, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and the required other ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred preparation methods are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredients from a previously sterile-filtered solution. The proper fluidity of the solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin.
[0385] The IL-2 agents described herein can be administered by a variety of methods. Several are known in the art, and for many therapeutic, prophylactic, or diagnostic applications, a suitable route / mode of administration is intravenous injection or infusion. For example, the IL-2 agents can be administered at a dose of about 1-100 mg / m 2 , preferably about 5 to 50 mg / m 2 , about 7~25mg / m 2 , more preferably about 10 mg / m 2The drug may be administered by intravenous infusion at a rate of less than 10 mg / min, preferably 5 mg / min or less, to reach a dose of 10 mg / min. As will be appreciated by those skilled in the art, the route and / or mode of administration will vary depending on the desired results. In certain embodiments, the active compound may be prepared with a carrier that protects the compound from rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, may be used. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, for example, Sustain and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978.
[0386] In one embodiment, the IL-2 agent is orally administered, for example, with an inert diluent or an assimilable edible carrier. The IL-2 agent (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into a tablet, or directly incorporated into the subject's diet. For oral therapeutic administration, the IL-2 agent may be incorporated into an excipient and used in the form of an ingestible tablet, buccal tablet, troche, capsule, elixir, suspension, syrup, wafer, and the like. To administer the IL-2 agent by a method other than parenteral administration, it may be necessary to coat the compound with a material or co-administer the compound with a material to prevent its inactivation. The therapeutic, prophylactic, or diagnostic composition may also be administered with a medical device, some of which are known in the art.
[0387] The dosage regimen is adjusted to provide the desired response (e.g., therapeutic, preventive, or diagnostic response). For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. For ease of administration and uniformity of dosage, it is particularly advantageous to formulate parenteral compositions in unit dosage form. As used herein, unit dosage form refers to a physically discrete unit suitable as a unitary dose for the subject to be treated, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specifications of the unit dosage form are determined by and directly depend on (a) the unique characteristics of the molecule and the specific therapeutic, preventive, or diagnostic effect to be achieved, and (b) the limitations inherent in the technology of compounding such molecules for the treatment of susceptibility in an individual.
[0388] Exemplary non-limiting ranges for therapeutically, prophylactically, or diagnostically effective amounts of an IL-2 agent are about 0.1-50 mg / kg, e.g., about 0.1-30 mg / kg, e.g., about 1-30, 1-15, 1-10, 1-5, 5-10, or 1-3 mg / kg, e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, or 50 mg / kg. The IL-2 agent is administered by intravenous infusion at a rate of less than 10 mg / min, e.g., 5 mg / min or less, to provide a total dose of about 1-100 mg / m 2 , for example, about 5 to 50 mg / m 2 , about 7~25mg / m 2 , for example, about 10 mg / m 2 It is to be noted that dosage values may vary depending on the type and severity of the condition to be alleviated. It should be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the composition, and the dosage ranges described herein are merely exemplary and are not intended to limit the scope or practice of the claimed compositions.
[0389] The pharmaceutical compositions herein may include a "therapeutically effective amount," a "prophylactically effective amount," or a "diagnostically effective amount" of the IL-2 agents described herein.
[0390] A "therapeutically effective amount" refers to an amount effective at dosages and for periods of time necessary to achieve a desired therapeutic result. A therapeutically effective amount of a polypeptide (e.g., an antibody molecule or fusion protein) may vary depending on factors such as the individual's condition, age, sex, and weight, as well as the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or detrimental effects of the antibody molecule are outweighed by the therapeutically beneficial effects. A "therapeutically effective dose" typically inhibits a measurable parameter by at least about 20%, e.g., at least about 40%, at least about 60%, or at least about 80%, compared to an untreated subject. The measurable parameter may vary, for example, based on the disorder being treated. The ability of the IL-2 agent to inhibit a measurable parameter can be evaluated in an animal model system predictive of efficacy in treating or preventing the disorders described herein. Alternatively, this property of the composition can be evaluated by examining the ability of the IL-2 agent to modulate the biological function of a target molecule or cell, for example, by in vitro assay.
[0391] A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
[0392] A "diagnostically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired diagnostic result. Typically, a diagnostically effective amount is an amount by which a disorder, such as those described herein, can be diagnosed in vitro, ex vivo, or in vivo.
[0393] In one embodiment, the pharmaceutical composition is a Good Manufacturing Practice (GMP) grade pharmaceutical composition. In one embodiment, the pharmaceutical composition has a purity of more than 99%, for example, more than 99.5%, 99.8%, or 99.9%. In one embodiment, more than 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% of the contaminants in the pharmaceutical composition are removed. In one embodiment, the pharmaceutical composition is large scale, for example, at least 20g, 30g, 40g, 50g, 100g, 200g, 300g, 400g, 500g, 600g, 700g, 800g, 900g, 1000g, or more.
[0394] The present disclosure also provides kits that include the IL-2 agents described herein. The kits may include one or more other components, including instructions for use, e.g., an antibody molecule conjugated to a label or therapeutic agent or other reagent useful for chelating or otherwise conjugating the radioprotective composition, equipment or other materials for preparing the IL-2 agent for administration, a pharma- ceutically acceptable carrier, and equipment or other materials for administration to a subject.
[0395] nucleic acid The disclosure also provides a nucleic acid comprising a nucleotide sequence encoding an IL-2 agent described herein.
[0396] In one embodiment, the nucleic acid comprises a nucleotide sequence that encodes the amino acid sequence of an IL-2 variant described herein, or a nucleotide sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and / or a sequence that is capable of hybridizing under stringency conditions described herein). In one embodiment, the nucleic acid comprises a nucleotide sequence that encodes an IL-2 variant that includes one or more of the mutations described herein.
[0397] In one embodiment, the nucleic acid further comprises an Fc region, e.g., a nucleotide sequence encoding an Fc region described herein, or a nucleotide sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto and / or capable of hybridizing under stringency conditions described herein). In one embodiment, the Fc region comprises one or more mutations, e.g., one or more mutations described herein. In one embodiment, the nucleic acid comprises, from the 5' to 3' direction, a nucleotide sequence encoding an IL-2 variant described herein and a nucleotide sequence encoding an Fc region described herein.
[0398] In another embodiment, the nucleic acid further comprises a nucleotide sequence encoding a linker, e.g., a linker described herein, or a nucleotide sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto and / or capable of hybridizing under stringency conditions described herein). In one embodiment, the nucleic acid comprises, in the 5' to 3' direction, a nucleotide sequence encoding an IL-2 variant described herein and a nucleotide sequence encoding a linker described herein. In one embodiment, the nucleic acid comprises, in the 5' to 3' direction, a nucleotide sequence encoding a linker described herein and a nucleotide sequence encoding an Fc region described herein.
[0399] In another embodiment, the nucleic acid comprises a nucleotide sequence encoding an IL-2 fusion protein, such as, for example, an IL-2 fusion protein described herein, or a nucleotide sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto and / or capable of hybridizing under stringency conditions described herein). In one embodiment, the nucleic acid encoding the IL-2 fusion protein comprises, in the 5' to 3' direction, a nucleotide sequence encoding an IL-2 variant described herein, and a nucleotide sequence encoding an Fc region described herein. In one embodiment, the nucleic acid encoding the IL-2 fusion protein comprises, in the 5' to 3' direction, a nucleotide sequence encoding an IL-2 variant described herein, a nucleotide sequence encoding a linker described herein, and a nucleotide sequence encoding an Fc region described herein.
[0400] In one embodiment, the nucleic acid comprises a portion of a nucleotide sequence described herein, which may encode, for example, one, two, or all of an IL-2 variant, a linker, or an Fc region.
[0401] In one embodiment, the nucleic acid comprises a nucleotide sequence encoding an amino acid sequence set forth in Table 9, or a functional fragment thereof. In one embodiment, the nucleic acid comprises a nucleotide sequence set forth in Table 10.
[0402] In one embodiment, the nucleic acid comprises a nucleotide sequence encoding the amino acid sequence of any of SEQ ID NOs: 2-38 or 1000-1002, or a functional fragment thereof. In one embodiment, the nucleic acid comprises a nucleotide sequence encoding the amino acid sequence of any of SEQ ID NOs: 56-359 or 1004-1009, or a functional fragment thereof.
[0403] In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 361-398 or 1010-1012, or a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or a nucleotide sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides. In one embodiment, the nucleic acid further comprises a nucleotide sequence of any of SEQ ID NOs: 399-407 or 1013, or a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or a nucleotide sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 nucleotides. In one embodiment, the nucleic acid further comprises a nucleotide sequence of any of SEQ ID NOs: 408-415.
[0404] In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 416-481 or 1014-1019, or a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or a nucleotide sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 nucleotides. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 416-453 or 1014-1019. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 454-491. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 492 to 529. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 416 to 453. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 454 to 491. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 492 to 529. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 530 to 567. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 568 to 605. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 606 to 643. In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 644 to 681.
[0405] In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 364, 365, 371, or 1010-1012, or a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or a nucleotide sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides. In one embodiment, the nucleic acid comprises a nucleotide sequence of SEQ ID NO: 364. In one embodiment, the nucleic acid comprises a nucleotide sequence of SEQ ID NO: 365. In one embodiment, the nucleic acid comprises a nucleotide sequence of SEQ ID NO: 371. In one embodiment, the nucleic acid comprises a nucleotide sequence of SEQ ID NO: 1010. In one embodiment, the nucleic acid comprises a nucleotide sequence of SEQ ID NO: 1011. In one embodiment, the nucleic acid comprises the nucleotide sequence of SEQ ID NO:1012.
[0406] In one embodiment, the nucleic acid further comprises the nucleotide sequence of SEQ ID NO: 1013, or a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or a nucleotide sequence which differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 nucleotides. In one embodiment, the nucleic acid further comprises the nucleotide sequence of SEQ ID NO:48.
[0407] In one embodiment, the nucleic acid comprises a nucleotide sequence of any of SEQ ID NOs: 1014-1017, or a nucleotide sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or a nucleotide sequence that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides. In one embodiment, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 1014. In one embodiment, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 1015. In one embodiment, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 1016. In one embodiment, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 1017. In one embodiment, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 1018. In one embodiment, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 1019.
[0408] In one embodiment, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 364. In one embodiment, the nucleic acid compris...
Claims
1. An IL-2 agent as described herein, such as an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of treating transplant rejection or a symptom thereof in a subject.
2. An IL-2 agent as described herein, such as an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of preventing transplant rejection or a symptom thereof in a subject.
3. An IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of modulating (e.g., increasing or inducing) transplant immunosuppression in a subject.
4. The IL-2 agent for use according to any one of claims 1 to 3, wherein said subject has undergone, is undergoing or is going to undergo a transplant at the time said IL-2 agent is administered to said subject.
5. An IL-2 agent as described herein, such as an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of conditioning said subject prior to transplant.
6. An IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, for use in a method of selectively increasing Tregs in a subject, wherein the subject has received, is receiving, or will receive a transplant.
7. The IL-2 agent for use according to any one of claims 1 to 6, wherein said transplant is a heart transplant.
8. An IL-2 agent as described herein, e.g., an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, in combination with heart transplantation, for use in a method of treating a cardiac disease or symptom thereof in a subject.
9. The method of claim 8, wherein the heart transplant is provided to the subject prior to, simultaneously with, or after administration of the IL-2 fusion protein.
10. 10. The IL-2 agent for use according to any one of claims 1 to 9, wherein the level of Tregs in the subject is increased by about 2, 3, 4, 5, 6, 7, 8, 9, 10 fold or more compared to the level of Tregs in the subject prior to administration of the IL-2 fusion protein.
11. The IL-2 agent for use according to claim 10, wherein the level of Tregs is determined in a sample from the subject.
12. The IL-2 fusion protein corresponds to human IL-2 (SEQ ID NO: 1031), (i) (a) the amino acid substitution H16L or H16N, (b) the amino acid substitution I92S, or (c) both (a) and (b), and (ii) An IL-2 agent for use according to any one of claims 1 to 11, comprising the amino acid substitutions V69A, Q74P, and C125S, IL-2 variant.
13. The IL-2 agent for use according to claim 12, wherein said IL-2 variant further comprises said amino acid substitution T3A.
14. 14. The IL-2 agent for use according to any one of claims 1 to 13, wherein said IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence that is at least 95% identical thereto or differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.
15. The IL-2 agent for use according to any one of claims 1 to 14, wherein said IL-2 fusion protein further comprises an Fc region.
16. The IL-2 agent for use according to claim 15, wherein said Fc region comprises an Fc region of IgG1 allotype m3 comprising an N297G substitution according to EU numbering.
17. 17. The IL-2 agent for use according to claim 15 or 16, wherein the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, an amino acid sequence that is at least 95% identical thereto, or differs therefrom by no more than 1, 2, 3, 4, or 5, 6, 7, 8, 9, or 10 amino acids, or a functional fragment thereof.
18. The IL-2 agent for use according to any one of claims 15 to 17, wherein the Fc region is fused to the C-terminus of the IL-2 variant.
19. The IL-2 agent for use according to any one of claims 1 to 18, wherein said IL-2 fusion protein further comprises a linker.
20. The linker is 4 S) 4 20. The IL-2 agent for use according to claim 19, comprising: (SEQ ID NO: 48).
21. 21. The IL-2 agent for use according to any one of claims 1 to 20, wherein the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008, or 1009, an amino acid sequence that is at least 95% identical thereto or differs therefrom by SEQ ID NOs: 1, 2, 3, 4, or 5, 6, 7, 8, 9, or no more than 10 amino acids, or a functional fragment thereof.
22. The IL-2 agent for use according to any one of claims 1 to 21, wherein said fusion protein forms a dimer.
23. The IL-2 medicament for use according to any one of claims 1 to 22, further comprising administering to said subject an immunosuppressant.
24. 24. The IL-2 agent for use according to claim 23, wherein the immunosuppressant comprises rapamycin.
25. The IL-2 agent for use according to any one of claims 1 to 24, wherein the subject is a human or a non-human primate.
26. The IL-2 agent for use according to any one of claims 1 to 24, wherein the subject is a mouse.
27. Combinations, including an IL-2 agent as described herein, such as an IL-2 variant as described herein, or an IL-2 fusion protein as described herein, and a transplant.
28. 28. The combination of claim 27, wherein the transplant is a heart transplant.
29. 29. The combination of claim 27 or 28, further comprising one or more additional immunosuppressants, such as rapamycin.
30. A combination according to any one of claims 27 to 29 for use in the treatment or prevention of transplant rejection in a subject.
31. 31. The combination for use according to claim 30, wherein said transplant rejection is heart transplant rejection.
32. The combination for use according to claim 30 or 31, wherein said IL-2 agent is administered to said subject before, during and / or after said transplantation.
33. A combination according to any one of claims 27 to 29 for use in modulating (e.g. increasing or inducing) immunosuppression in a subject.
34. A combination according to any one of claims 27 to 29 for use in selectively increasing T regulatory cells in a subject.
35. The combination according to any one of claims 30 to 34, wherein the subject is a human or a non-human primate.
36. The combination according to any one of claims 30 to 34, wherein the subject is a mouse.
Citation Information
Patent Citations
Regulation of IL-2 and IL-15 mediated T cell responses
JP2004525076A
Aglycosylated fc-containing polypeptide
JP2016514161A
Interleukin-2 mutein for regulatory T cell proliferation
JP2016518823A
Interleukin-2 mutant protein for proliferation of regulatory T cells
JP2018512151A
Interleukin-2 agents and uses thereof
WO2021021606A1
